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SUMMARY 
	
Viruses have minimal survival requirements thus ensuring their survival in harsh 
conditions but are unable to replicate independently. To overcome this, they hijack host 
resources and exploit host machinery for their benefit. These factors enable virus replication 
in the first place thus infecting the host but perhaps rather counterintuitively they are also 
necessary to ensure virus replication in antigen presenting cells (APCs) to ensure virus 
antigen processing and presentation ensuring immune activation such that the infection can 
be cleared. 
Innate and adaptive immune system works side-by-side in order to effectively combat 
infections. We have shown that enforced virus replication in splenic CD169+ macrophages is 
crucial for immune activation. In this study, we have identified a novel function of a 
transcription factor known for its crucial role in cell replication and proliferation. The present 
study thus deals with elaborating the role of B-Myb in virus replication and exploring the 
therapeutic effect of LCMV replication in tumors. 
B-Myb is an important transcription factor for cell proliferation, member of DREAM 
complex and is also known to induce expression of multiple genes. Here, we show that B-
Myb is also a major transcription factor activated during virus replication and helps the virus 
by maintaining the expression of various host-factors required for virion production and 
release. We observed that activation of B-Myb on viral replication is not cell-specific. We 
show that B-Myb dependent early virus replication in spleen is crucial for adaptive immune 
activation and thus anti-viral response in both RNA and DNA viruses. We also show here 
that B-Myb dependent replication is also a requirement for human viruses HSV and HIV. In 
the second portion of the thesis we explored the effect of B-Myb dependent LCMV 
replication in tumors. Interestingly, we show the potential of LCMV as anti-tumor virotheray 
which when compared to oncolytic viruses, is comparable or more effective. We 
demonstrated that LCMV treatment induces evasive immune infiltration in tumors. We show 
that LCMV treatment leads to tumor regression via IFN-I producing Ly6C+ monocytes which 
acts as anti-angiogenesis.   
In conclusion, we have identified a new function of B-Myb as host factor facilitating 
the replication of multiple viruses. We demonstrated the importance of B-Myb in early virus 
replication for immune activation and infection control. We also established LCMV as an 
IFN-I dependent anti-tumor therapy. 
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ZUSAMMENFASSUNG 
	
	 Viren besitzen eine minimale Überlebensausstattung, die ihren Fortbestand in 
widrigen Umständen sichert, aber sie nicht zur unabhängigen Reproduktion befähigt. 
Letzteres zu kompensieren, berauben sie die Resourcen ihres Wirts und beuten die Wirts-
Maschinerie zu ihrem Vorteil aus. Diese Faktoren ermöglichen in erster Linie die Virus-
Replikation und führen daher zur Infektion des Wirts. Sie sind aber auch - vielleicht eher 
kontraintuitiv – nötig zur Sicherung der Virusreplikation in antigen-präsentierenden Zellen 
(antigen presenting cells; APCs), wodurch es zur Antigen-Prozessierung und -Präsentation 
kommt, welche widerum die Immunaktivierung auslöst, damit die Infektion beseitigt werden 
kann. 
 Das angeborene und das adaptive Immunsystem arbeiten nebeneinander, um 
Infektionen effektiv zu bekämpfen. Wir haben gezeigt, dass eine verstärkte Virusreplikation 
in den CD169+ Makrophagen der Milz wichtig für eine Immunaktivierung ist. In dieser 
Arbeit haben wir eine neue Funktion eines Transkriptions-Faktors identifiziert, der bereits für 
seine bedeutende Rolle in Zellreplikation und -proliferation bekannt ist. Die vorliegende 
Arbeit erarbeitet Rolle von B-Myb in der Virus-Replikation und untersucht den 
therapeutischen Effekt einer LCMV-Infektion bei Tumoren. 
 B-Myb ist ein wichtiger Transkriptionsfaktor für Zellproliferation, Mitglied des 
DREAM-Komplexes und bekannt dafür, die Expression vielzähliger Gene zu induzieren. 
Hier wird gezeigt, dass B-Myb auch ein bedeutender Faktor ist, der während der Virus-
Replikation aktiviert wird und dem Virus hilft, indem er die Expression verschiedener Wirts-
Faktoren erhält, die für die Virion-Produktion und -Freisetzung benötigt werden. Wir haben 
beobachtet, dass die Aktivierung von B-Myb bei der Virus-Replikation nicht zell-spezifisch 
ist. Wir zeigen, dass B-Myb-abhängige frühe Virus-Replikation in der Milz wichtig für die 
Aktivierung des adaptiven Immunsystems und somit der anti-viralen Antwort ist und das 
sowohl bei RNA- als auch DNA-Viren.  
 Zudem wird gezeigt, dass die B-Myb-abhängige Replikation eine Bedingung für die 
humanen Viren HSV und HIV ist. Im zweiten Teil der Arbeit wird der Effekt von B-Myb 
abhängiger LCMV-Replikation bei Tumoren untersucht. Interessanterweise, decken wir das 
Potential von LCMV als Anti-Tumor-Therapeutikum auf, dass verglichen mit onkolytischen 
Viren vergleichbar oder sogar effektiver ist. Wir demonstrieren, dass eine LCMV-
Behandlung ein Eindringen von Immunzellen in Tumore bewirkt. Darüberhinaus wird 
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gezeigt, dass eine LCMV-Behandlung zur Tumor-Regression aufgrund von IFN-I 
produzierenden Ly6C+ Monozyten führt, welches anti-angiogenetisch wirkt. 
 Zusammenfassend haben wir eine neue Funktion von B-Myb als Wirtsfaktor 
identifiziert, der die Replikation mehrerer Viren vereinfacht. Wir zeigten die Wichtigkeit B-
Myb’s für die frühe Virus-Replikation, Immun-Aktivierung und Infektionskontrolle auf. 
Zudem etablierten wir LCMV als eine IFN-I-abhängige Anti-Tumor-Therapie.	
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CHAPTER-1 
INTRODUCTION 
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Organisms are constantly evolving in order to adapt and survive the changing 
environment and survival needs. Humans (Homo sapiens sapiens) are constantly surrounded 
by different kinds of pathogens that range from viruses to bacteria to parasites. Among these, 
viruses present an interesting scenario with their dependence on the host for replication and 
propagation. Viruses use host resources in order to replicate and to evade immune response in 
order to facilitate survival. The host relies on its immune system to extradite pathogens.   
Immune system represents an organized set of cells and molecules that function as a defence 
against the pathogens, allergens and various other foreign elements. The immune system 
functions in two fundamentally different responses namely innate (humoral) response and 
acquired (adaptive) response. The innate response behaves in the same way every time it 
encounters an antigen whereas acquired immune response improves upon repeated exposure 
to the antigen.  
1.1 Immune System 
1.1.1 Innate immunity: 
Living organisms have constantly been threatened by different pathogens, which in 
turn use them for their survival. With the constant evolution of pathogens and emergence of 
new pathogens, both invertebrates and vertebrates have also evolved multiple ways to tackle 
them. The first line to response that both the invertebrates and vertebrates have is the innate 
immune response.  
Innate immune system is the ancient form of host response against invading 
pathogens and it is universal. It’s present in all vertebrates and invertebrates and thus can be 
conferred that it evolved before divergence into kingdoms. This part of immune system 
covers quite an extensive area of host defence which includes recognition of pathogen 
associated molecular patterns (PAMP), and also lies behind most of the inflammatory 
response. Functionality of innate immune response relies on innate immune receptors or 
germline-encoded recognition receptors which in-turn sense various microbial metabolites 
produced by pathogens.  Innate immune system comprises of many cells, except for B and T 
lymphocytes of the adaptive system. To be more specific, the cells which functions as the 
base of innate immune system are macrophages, dendritic cells (DC), mast cells, neutrophils, 
eosinophils and NK cells. Activation of these cells during an inflammatory response can be 
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considered as a sign of pathogenic infection. These cells, upon encountering a pathogen 
divide and differentiate rapidly into effector cells for elimination of infection. Considering a 
scenario where innate immune system fails to control the infection, it instructs the adaptive 
immune system about the infection and nature of pathogenic challenge.  
This is done by expression of co-stimulatory molecules such as CD80, CD86 on the surface 
of specialized antigen presenting cells, dendritic cells. The innate immune system is 
composed of many factors that all together results in effective functioning of this system. 
 
1.1.1.1 Pattern Recognition Receptors:  
 Innate immune system employs a variety of receptors that are expressed on the cell 
surfaces, intracellular compartments, secreted into the body to recognize and neutralize 
antigen/antigen infected cells. These receptors are called pattern recognition receptors (PRR). 
The functional aspect of these includes opsonisation, phagocytosis, complement system and 
proinflammatory pathway activation and induction of apoptosis.  
Secretory PRR: These include Mannan-binding protein (MBP), C-reactive protein (CRP) and 
serum amyloid protein (SAP). These are produced by liver during infection. Primary roles of 
these include opsonisation and activation of classical complement pathway. With the 
different binding affinities, these covers a wide array of pathogens. CRP and SAP bind to 
phosphorylcholine whereas MBL binds specifically to terminal mannose residues. 
Intracellular PRR: Intracellular access of several pathogens, while evading the immune 
system requires an effective recognition of these in cellular compartments. Protein Kinase 
(PKR) are group of proteins, which are activated upon dsRNA binding1, during viral 
infection. PKR further activates NF-kB and MAP kinase pathways leading to type-I 
interferon dependent response and also inactivates eIF2a which blocks cellular role in viral 
protein synthesis. Other PRR includes 2’-5’-oligoadenylate synthase (OAS)/RNaseL2, which 
also gets activated upon dsRNA binding and acts by degrading the viral RNA and cellular 
RNA of infected cells leading to apoptosis. NOD family acts as a PRR in multiple ways. It 
contains N-terminal CARD domain, nucleotide binding domain (NBD) and C-terminal 
leucine rich element (LRR) region3, 4. They act by RIP2 which further activates NF-kB and 
MAP kinase pathways3-5. 
Toll Like receptors: TLR’s or Toll Like receptors functions by sensing conserved molecular 
motifs known as PAMPs. These PAMPs are found in variety of pathogens which include 
bacteria, protozoa, fungi and viruses6-9. More than ten TLRs have been discovered in 
Piyush	Sharma	 7	
	
mammals till now and differs in expression patterns and ligand specificities. Several TLRs 
are expressed on pDC to encounter and recognize viral components such as viral RNA and 
DNA. Among these, TLR2, 3, 4, 7 and 9 recognize viral components whereas TLR2 and 4 
are critical for recognition of bacterial components and are present on plasma membrane10. 
All TLRs except for TLR3 acts via myeloid differentiation factor 88 (MyD88)10 which 
further goes down to activate NF-kB signalling pathway whereas TLR3 acts via recruitment 
of TIR-domain containing adaptor inducing IFN-b (TRIF)11, 12. All together viral nucleotides 
recognition by TLR is controlled as per their localization as well as their ligands. 
 
1.1.1.2 Cellular components: 
 Innate immune compartment consists of cells from the myeloid lineage. These cells 
include mononuclear and polymorphonuclear phagocytes. Mononuclear phagocytes include 
macrophages and dendritic cells whereas polymorphonuclear phagocytes consist of 
neutrophils, basophils and eosinophils13. 
1.1.1.2a Macrophages:  
 These mononuclear phagocytes were discovered in late 1800 by Elie Metchnikoff and 
named as “Big eaters” in Greek for their astonishing ability of phagocytosis. These are 
resident cells in lymphoid and non-lymphoid tissues. The role of macrophages is not limited 
to an immune effector cell but also acts as by removing the cellular debris during the tissue 
remodelling and apoptosis of the cells. These cells are present in virtually every tissue and 
arise from blood-circulating monocytes. The tissue macrophages are long-lived and are 
involved in the early host immune response. Functional role of macrophages can be circled 
into three main categories host-defence, wound healing and immune regulation14. Broadly 
they are functionally classified into M1 and M2 macrophages. The former is considered as 
“killer” macrophages and secrete high levels of IL-12 on activation, whereas latter are more 
anti-inflammatory and are involved in tissue repair and wound healing.  
Tissue resident macrophages are group of heterogeneous populations of cells that 
functions in tissue-specific way. These acquire different name based on their residing 
location. These macrophages are seeded into different organs during the embryonic stage and 
then differentiate into different resident macrophages guided by the tissue microenvironment 
cytokines and metabolites. 
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Figure 1: Tissue resident macrophages and their differentiation determinants (Lavin, Y. et. 
al., Nat. Rev. Immunol. 2015) 
 
Among these, are the marginal zone macrophages of the spleen and LN which are 
characterized by the surface marker CD169. These cells are shown to be important for early 
virus replication15 and thus in processing and presentation of antigen to adaptive immune 
cells.  
 
1.1.1.2b Dendritic cells:  
 These cells were discovered by Ralph Steinman in 197316 and named after Greek 
word “Dendron” meaning tree. DC’s are specialized in antigen processing and excellent 
stimulators of T-cells. Further discovery led to another major milestone showing expression 
of both major histocompatibility complex (MHC)17, 18 by them as well as to initiate and 
antigen-specific immune response by processing antigen protein. DCs have differentiated into 
different subsets depending on their location and function. These subsets basically include 
classical DC(cDC), plasmacytoid DC (pDC) and monocyte-derived DC (moDC)19, 20. These 
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all play different role during an immune response. cDC are found in lymphoid organs as well 
as in most of the non-lymphoid organs. These are basically involved in antigen processing 
and presentation to adaptive immune cells. These then migrate as well as depending on the 
maturation stage express/overexpress various co-stimulatory molecules such as CD40, CD80, 
CD86, MHC-II. pDCs on the other hand are characterized by their constant presence in blood 
and in peripheral organs21. These have a constituent expression of IRF7 and thus act as potent 
stimulator and producer of type-I interferon upon infection22, 23. moDCs or imflammatory DC 
originate from monocytes infiltrates during inflammation. These possess similar expression 
profile as of cDC, differing in CD64 and Fc-gamma receptor 1 (FcgR1) expression24, 25. 
These cells efficiently stimulate T cells like cDC but requires more elaborate research on 
their distinct expression profile. 
 
1.1.1.2c Polymorphonuclear phagocytes:  
 These granular players play key roles in the containment of infection. These cells 
mature in bone marrow and then enter blood circulation in their fully differentiated form. 
They remain in the G0 stage for their short life span, unless triggered by external stimuli. 
Neutrophils acts by expanding rapidly during course of infection and possesses a vast array 
of effector molecules to eliminate the infection. These are thus often known as specialized 
killers. Basophils and eosinophils particularly respond to the cytokines secreted by adaptive 
system and thus helps in shaping of immune milieu13. Mechanism of function of these 
granulocytes is also via release of these granules which comprises of proteolytic enzymes, 
cytotoxins, antimicrobial peptides, etc. along with production of cytokines, chemokines and 
pro-inflammatory molecules26-28.  Neutrophils and eosinophils also produces ROS as an 
immune response29, 30. These cells migrate to the inflammation site in response to 
chemoattractants. Granulocytes can be identified with the expression of Gr-1, which can be 
sub divided into Ly6G and Ly6C. Ly6G markers on them along with CD11b. Reports have 
shown that F4/80 antibody also binds to Ly6G presenting population. Ly6C is enriched in 
monocytic myeloid lineage31.   
 
1.1.2 Adaptive Immunity: 
 
 Adaptive immunity is the second type of immune response constituted by the host. 
All the vertebrates harbour this type of immunity along with innate immunity. This part of 
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immune system allows the host to embark an immune response in case of new pathogens and 
to make a memory against them. This is an important feature as it enables the host to launch a 
heightened response against the pathogen upon re-encounter. 
Adaptive immune system comprises of two primary sets of cells; T cells and B cells. These 
cells are further divided into many subsets which arises on functionality and situational 
needs. 
 
1.1.2.1 T cells:  
These cells originate from haematopoietic compartment of bone marrow and then 
migrate to thymus for maturation. These double negative cells (DN) (neither CD4, nor CD8) 
are also known as committed T-cells precursor. These DN cells further give rise to either gd 
or αβ TCR-expressing cells. In case of TCR- αβ, re TCR-α and β undergo sets of somatic 
rearrangements under the control of recombination-activating gene-1 and 2 (RAG1, RAG2)32, 
33, deficiency of which leads to immature T-lymphocyte34 and eventually elimination. Post 
rearrangements, thymocytes begin to express CD8 and CD4 receptors as double positive cells 
(DP cells). DP cells then undergo stringent selection process based on their ability of interact 
with self-peptide-MHC I and II presented by cortical epithelial cells. These processes can be 
characterized as positive and negative selection. Finally cells which can recognize self-
ligands are further differentiated into mature cytotoxic T cells (CD8+) or T-helper cells 
(CD4+)35. T-cell recognizes antigen presented by APCs via MHC-I and II complex. 
 
1.1.2.1a Cytotoxic T-cells: 
  These are involved in elimination of infection, when triggered they undergo clonal 
proliferation into effector cells which produce perforin, granzyme and granulysin36. First 
shown as a subset of T-lymphocytes involved in in-vitro cell mediated lysis of target cells37, 
38, these cells were then  identified to present dual specificity against viral antigen plus self-
MHC39, 40. Activation of CD8+ cells in done via APC interaction, upon which naïve CD8+ T-
cell migrate to peripheral regions of the tissue leading to its differentiation into effector and 
memory cells41, 42. This rapid expansion of cells in associated with enhanced metabolic 
activity involving rapid aerobic glycolysis, which is shown to be triggered by CD28-induced 
PI-3K-mTOR, TCR-ERKsignalling43, 44. The antiviral response of these cell can be accounted 
by production of IFNg and TNFa. The differentiation of naïve CD8+ cell to effector and 
memory cells in governed by expression of multiple genes as well as cytokines after antigen 
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primimg45. IL12 promotes effector T-cell development via T-bet induction whereas IL-2 
cytokine promotes expression of transcriptional repressor Blimp-1, which in-turn leads 
towards the effector cell formation decreasing the memory cell formation46 (Fig.2). Memory 
CD8+ cell differentiation is promoted by factors such as Ecf-1, Bcl-6 and Eomes. Memory 
cell are long-term persisting cells which arises during the late infection phase. These cells 
persist in antigen and TCR-independent but cytokine-dependent manner47, 48. The role of 
memory CD8+ T-cell is to provide rapid proliferation and expression of effector molecules 
during re-encounter of the antigen to launch an immediate effective response. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Effector of CD8+ T-cells Differentiation 
 
1.1.2.1b Th cells: 
  These cells possess no cytotoxic or phagocytic characteristic but rather they play a 
crucial role in enhancing and establishing an immune response.  CD4+ T cells differentiate 
into numerous subsets which are characterized by their cytokine profile and CD expression 
profile. These include Th1, Th2, Th9, Th17, Th22, Tfh (Follicular helper T-cells) and Tregs 
(Regulatory T-cells)49. Once activated via recognition of antigen bound to MHC-II, they act 
via secretion and regulation of different cytokines. Each subset is differentiated via specific 
cytokines49, 50 (Fig. 3). Th1 response can be recognized by production of interferon-gamma 
(IFN-g) and TNF which further enhances bactericidal activities of macrophages and induction 
of B-cell response in neutralizing antibodies. Th2 on the other hand releases cytokines 
(Interleukin-4, 5 and 13) which further activates and recruits IgE producing B cells, mast 
cells and eosinophils36. Th9 produces IL9, Th17 produced IL17 thereby promoting host 
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defense in bacterial and fungal infection. Post clearance of infection, effector T cells and Th 
cells are cleared by phagocytosis with few remaining as memory T-cells which can rapidly 
transform into effector upon relapse of infection51. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: Th differentiation upon antigen recognition. (Kaplan, M.H., et. al., Nat. Rev. 
Immunol. 2015) 
 
1.1.2.2 B-cell:  
 With the early indication of existence of these cell in 1890 with the recognition of 
proteins secreted by B-cells then known as serum globulins, B-cells were formally introduced 
in 1965 by M.D. Cooper52. This is the population of cells which can be defined by its 
expression of clonally diverse cell surface protein known as immunoglobulins (Ig) receptors 
recognizing specific antigenic epitopes. In addition, B-cell have other function which 
includes antigen presentation and regulatory cytokine production53. These cells are 
continuously produced in the bone marrow54 with a short life span. Early development 
involves rearrangement of H and L chains of Ig, leading to Pre-BCR (in murine) or Pre-B-
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cell (in humans), these arise from progenitor B-cells (pro B-cell) which lacks expression of 
both pre-BCR and surface Ig. Later development of B-cell occurs in an antigen-independent 
manner via process of ordered combinatorial rearrangement of V, D and J segments in H 
chain locus and V and J segment in L chain loci55 which results in the very diverse repertoire 
of VDJH and VJL functional rearrangements56, collectively forming B-cell receptor (BCR). 
These rearrangements are triggered/stimulated by variety of stimuli such as marrow stromal-
cell derived IL-757, FLT3 ligand, E2A, EBA and Pax5 transcription factors58. BCR 
expression during the development of B-cells presents a crucial objective for B-cell 
development and their survival in the periphery59. On the other hand, antigen induced B-cell 
development, differentiation and activation occurs in secondary lymphoid organs governed 
by dynamic changes in gene expression forming germinal center (GC) reaction. GC reaction 
plays a crucial role in B-cell mediated immunity as they contain rapidly proliferating cells 
generates diverse high affinity-Ig secreting plasma cells and memory B-cells60 against the 
antigen. The signature of GC reaction can be characterized by clonal expansion, somatic 
hypermutation at VH genes, recombination in class switching at IgH locus and affinity 
maturation of a BCR for its unique antigenic epitope.  
 
1.2 B-Myb (Mybl2): 
 
The myb gene is a proto-oncogene and was initially isolated in 1941 by W.J. Hall. It 
is a family of three conserved homologous proteins A-Myb, B-Myb and C-Myb. Among 
these, B-Myb is a powerful molecule with a plethora of interacting partner with which it 
exerts its effects on crucial cellular functions such as cell proliferation, apoptosis, senescence, 
cell metabolism and mitosis. This vast spectrum of its function has led to the interest in this 
molecule and its family. 
After decades of modifications, molecular cloning and analysis of v-myb revealed the 
evolutionary conserved proto-oncogene c-myb61.  In the late 1980s’, A-Myb and B-Myb was 
discovered by screening of human T-cell cDNA library which was probed using C-Myb 
probe at low strigency62, 63. This family is mainly characterized by the presence of an 
evolutionary conserved DNA-binding domain of 50 amino acids64 and binds to the same 
consensus sequence (PyAAC(G/T)G)61, 65. Thus, collectively myb family represents a group 
of functionally diverse transcriptional activators, which are found in both plants and animals. 
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In animals, myb family members are transcriptional activators which are basically involved 
in cell proliferation66.  
 
1.2.1 Structure: 
  B-Myb, encoded by mybl2 gene and is ubiquitously expressed62. B-Myb shares an 
unique homology with A and C-Myb. It is composed as R1, R2 and R3 which are three 
tandem repeat sequence of 50 amino acids67 and marks the DNA binding site of the protein. 
Specifically, R1 is required for stabilization of DNA-R2R3 complex68 in which R2 and R3 
binds to DNA cooperatively.  These are followed by the acidic amino acid region responsible 
for transcription activation. The carboxy terminal of B-Myb is a negative regulatory domain 
and is involved in its transactivation function69 (Fig. 4). 
 
 
Figure 4: Schematic presentation of different domains of B-Myb protein (Jaoquin, M. and 
Watson, R.J. Cell Mol Life Sci, 2003) 
 
1.2.2 Function: 
B-Myb is widely accepted as the transcription factor having a role in cell proliferation 
and growth70. The expression of B-Myb is regulated via its E2F transcription family by 
binding to its E2F binding site at its promoter region71. Binding to E2F4 during G0/earlyG1-
phase have been shown to repress B-Myb transcription, whereas binding of E2F1/3 activates 
it in mid-late G1-phase72. B-Myb transcription starts at the onset of G1/S-phase which is 
gradually declined till G2M-phase and is functionally activated by cyclinA2-CDK2 
complex73, 74. B-Myb is different from its other family members as it is expressed in all 
replicating cells and shows strong association and functional relevance in cell cycle 
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progression75 and proliferation76-78. Activated state of B-Myb is denoted by its 
phosphorylation which also triggers its degradation via ubiquitin-dependent Cdc34-SCF 
pathway79. Crucial role of B-Myb in cell cycle regulation was shown by many reports along 
with the early stage embryonic lethality in B-Myb gene knockout mice80.  
Phosphorylation of B-Myb can be observed at its maximal level at the S-phase81 
which has been shown to be conducted via Cyclin-A2/Cdk2. Cyclin-E1 showed minimal or 
no effect whereas cyclin-B1 and D1 had no effect on B-Myb phosphorylation82, 83. Due to 
presence of multiple probable phosphorylation sites, various studies were done in order to 
identify the sites corresponding to Cyclin-A2/Cdk2 binding. These reports have identified 
numerous sites (T447, T490, T497, T524 and S581) which represent a preference to a 
consensus site (S/T-P-X-K/R) of Cyclin-A2/Cdk284, 85. Further studies identified 10 more 
phosphorylation sites each containing the consensus sequence S/T-P, which is known to be 
consistent with phosphorylation with Cdks. Phosphorylation of B-Myb causes two important 
functional triggers: (1) Crucial enhancement of its transcriptional activation properties and 
(2) it flags the protein for its degradation. Upon phosphorylation, B-Myb is localized to 
nuclear compartment which is triggered by multiple nuclear localization signals (NLS)86. 
Here B-myb acts binding directly to the Myb-binding sites in the genomic DNA and also via 
its interaction with transcription factors which further to certain genes87. Along with its own 
function of transcriptional activation of genes, B-Myb have been shown to interact with 
multiple partners in order to affect gene expression. One such scenario is of LINC/DREAM 
complex, in which B-Myb associates directly with MuVB (Dream) complex which comprises 
of E2F, p130, p107 and FOXM188. The dream complex acts as a master coordinator of the 
cell cycle dependent gene expression which when disturbed leads to shifting towards 
proliferation stage with increased mitotic gene expression level frequently leading to tumor 
development. Also, overexpression of B-Myb enables cells to escape the routine stages of 
cell cycle and arrest77 leading to uncontrollable growth65, 89. 
 
1.2.3 B-Myb in tumors:  
 As discussed above, B-Myb overexpression is associated with oncogenesis and poor 
prognosis65, 90. It has been shown that repression of B-Myb can inhibit the proliferation of 
both normal and tumor cells76, 78, 87, 91. This effect of B-Myb can also be contributed to its 
effect of increased expression of certain anti-apoptotic genes namely Bcl2, survivin, 
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clusterin, etc92-94. A number of reports have shown association of B-Myb in multiple tumors 
including hepatocellular carcinoma95, breast cancer96, colorectal cancer97 and lung cancer98.  
 
1.3 Viruses 
 
1.3.1 LCMV 
 LCMV is a prototypic member of arenaviridae family, discovered in 1933 by 
Armstrong and colleagues from the samples of an encephalitis epidemic99. It is a negative –
strand RNA virus with a cytoplasm restricted life-cycle with a bi-segmented genome. With 
spherical or pleomorphic virions ranging from 40-200nm, it has viral glycoprotein (GP) as 
spike like structure on lipid envelope arranged subjacent to Z-protein and 
ribonucleoproteins100 containing circular helical nucleocapsid with 400-1300nm in length. 
The genome consists of two negative ss-RNA molecules; small (3.5kb, S) and a large (7.2kb, 
L) segment, where small segment encodes the major components including viral 
nucleoprotein (NP) and glycoprotein (GP) precursors and Large segment encode viral RNA 
dependent polymerase and small zinc-finger structural protein Z. LCMV entry into the cell is 
initiated by binding to cellular receptors (a-Dystroglycan) with its GP-1 and GP-2 
glycoprotein101 and then endocytosed via uncoated endocytic vesicles. 
LCMV infection: LCMV represents a cytopathic virus whose infection outcome 
differs from different strains102. There is a total of four strains that are present and being used 
for research purposes. Docile is the aggressive strains variants of strain UBS originally 
derived from WE strain and are hepatotropic in nature whereas clone-13 is derived from 
Armstrong and is neurotropic in nature103. Infection with WE or Armstrong causes an acute 
infection which is cleared by the host within 10-15 days. On the other hand, infection with 
Docile or Clone-13 establishes a persistent chronic infection, which takes 8-12 weeks to 
clear. The infection also varies with the initial infective titer. Infection with lower plaque 
forming unit (PFU) of 102-105 PFU LCMV mounts a massive CD8+ T-cell expansion with 
neutralizing antibodies present by day 7. With higher PFU of >106, T-cell exhaustion104 
occurs after a weak CTL response. Infection with an intermediate PFU of 104 of Chronic 
LCMV, mounts a strong CTL response, which further leads to severe immunopathology.  
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1.3.2 VSV 
 VSV belongs to the genus Vesiculovirus in family of Rhabdoviridae and is a cytolytic 
virus. There are multiple variants have been isolated of VSV. The two principal strains which 
are used for research and medical purposes are VSV-New Jersey (VSV-NJ) and VSV-Indiana 
(VSV-IN). The former was isolated in New Jersey, USA in 1926 whereas the latter was 
isolated in Indiana, USA in 1925. VSV is a negative sense, ss-RNA, bullet shaped 
encapsulated virus with virion size of 70 ´ 200nm. VSV RNA consists of five genes that 
further encodes five major viral proteins namely the nucleoprotein (N), phosphoprotein (P), 
matrix protein (M), glycoprotein (G) and the large polymerase protein (L).  The phospholipid 
capsule of VSV mediates the entry into the cell in a clatherin-dependent fashion. 
VSV has been a model virus for its use in fields of molecular biology, virology and 
immunology. The simple structure, rapid replication rate and disease course, its broad tissue 
tropism all accounts for it favourable use in research105. VSV also exhibits neurotropism 
which represents the cause of host death in case of immune evasion by the virus106. In mouse 
models, if the VSV infection is not controlled efficiently enough during its early replication 
then virus escapes to CNS and then eventually breach blood-brain barrier reaching brain and 
causing paralysis with in 6-7 days of infection107. VSV is an interferon responsive virus 
whose control is majorly dependent on the antiviral antibodies. Infection of VSV leads to a 
major interferon secretion and is often used as to study the interferon response/to induce 
interferon response in pathogenesis. T-cell response on the other hand is quite limited in VSV 
infection, and T cells usually help in controlling the virus spread to vital organs. 
 
1.4 Interferon: 
	
 Interferon (IFN) was the first cytokine which was discovered in late 1950s by Isaacs 
and Lindenmann108 in their study of a secreted factor in influenza-virus infected chick cells. 
Being discovered as an antiviral agent, it has been named Interferon because of its ability to 
interfere with the viral replication. IFNs are a multigene family, categorized into Type-I and 
Type-II IFN (Fig. 5). The former is also known as viral IFNs which includes IFN-a 
(Leukocyte) and IFN-b (fibroblast) and are induced by virus infection, while the latter is also 
known as immune IFN and consists of IFN-g and are induced by mitogenic or antigenic 
stimuli. Type-I IFN is synthesized by most of the virally infected cell whereas Type-II IFN is 
only synthesized by special cells such as NK cells, CD4+ Th-1 and CD8+ T-cells. Viral IFN 
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are coded by 13 IFN-a and 1 IFN-b genes present on chromosome 9 in human, whereas in 
mouse it is coded by 14 IFN-a and 1 IFN-b (including 3 IFN-a pseudogenes) genes present 
on chromosome 4109. Induction of IFN are known to be done by two distinct ways; one is 
antigen processing and capture in endosomes or specialized mediator cells mediated by 
TLRs110 and the other is ubiquitously expressed cytosolic receptors sensing mechanism 
mediated by RIG-I111, MDA5 and DNA sensors. Presence of both interferons in the system 
ensure proper IFN induction despite of vast range of viruses and pathogens present.  
IFN exert their actions via their cognate receptor complex expressed on all cell types. Type-I 
IFN receptor is IFNAR-1 and IFNAR-2 while Type-II IFN receptor is IFNGR-1 and IFNGR-
2. The signalling involves the dimerization of IFNAR-1/2 with IFN-a/b and of IFNGR-1/2 
with IFN-g. IFN-mediated cellular signalling is done via JAK-STAT pathway as shown in 
Fig. 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5: Type-I and II IFN signalling via JAK-STAT. (Platanias, L.C., Nat. Rev. Immunol. 
2005) 
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1.4.1 Antiviral effect of Interferon: 
 Interferon is the primary step for the antiviral defense for a wide range of DNA and 
RNA viruses. IFN inhibition of viral multiplication cycles varies from early to late steps in 
different viruses. IFN induces proteins that further acts in anti-viral response, these are PKR, 
2’,5’-oligoadenylate synthetase (Oas), RNase L, RNA-specific adenosine deaminase and Mx 
protein GTPases112. Along with these IFN also induces nitric oxide synthase (iNOS2) and 
MHC-I and II, which plays crucial role in other anti-viral immune responses. Both IFN-a/b  
along with IFN-g are able to induce MHC-I thus promoting CTL recognition of antigen and 
NK cell, whereas IFN-g increases MHC-II expression on APCs, promoting antigen 
presentation to Th cells. IFN-I contributes via chemokines that results in activation and 
recruitment of NK and CTL, also they can activate NK cells directly113.  
 
1.4.2 Anti-tumoral effect of Interferon 
 IFN has been exploited for a long time for its anti-tumor capabilities. As discussed, 
IFN-I regulates activity of multiple cell types including DCs, macrophages, T-cells, B-cells, 
etc. IFN-I acts anti-tumor in a multi-faceted way. It has been shown to directly upregulate the 
expression of tumor-associated antigens (TAAs)114 along with activation of APCs to cross-
present TAA to T-lymphocytes115. Further IFN-I have been shown promote the recruitment 
of mature effector CD8+ T-cells along with negatively regulating proliferation of Tregs 
reducing the suppressive function on CTL activity116. Along with this, IFN-I also expresses 
an extrinsic effect on tumors via regulation of angiogenesis, where it inhibits the formation of 
new vessels by mediating a negative effect on expression of pro-angiogenic factors117.  
 
1.5 Host Factors 
	
 Viruses are formed of a nucleic acid component with a protein shell in a miniscule 
size with rare lipid bilayer that they use to bind to their host cell. These are infectious agents 
that completely rely on the host resources for their replication. Despite of the simplicity of 
the viral structure, they have evolved complex mechanisms to hijack cellular functions in 
order to ensure their replication118. Upon infection, viruses hijack the basic machinery of 
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transcription and translation to manufacture viral proteins. All these factors which are 
provided by the host cell and are consumed by virus are known as host-factors.  
Mammalian cells have a multitude of complex pathways and mechanisms to ensure 
the continuous and efficient functioning. This results in the precise activation and degradation 
of molecules to fulfill cellular energy and metabolic requirements along with transportation 
of molecules in and out of the cell. Viruses have been shown to utilize the cellular reserves 
and transport system to their advantage119, 120. Study of viral replication cycle proves to be 
crucial for the understanding of the infection and cellular response. Many such host factors 
for HIV121, HCV122, influenza123, dengue124, ebola125 virus etc. have been identified via 
genomic and proteomic analysis of infected host cells, involved in viral entry, transcription 
and translation and assembly of viruses. One such report identifying an kinase CDK-2 
dependent transcription of HIV-I126 elaborates the evasive exploitation of cellular resources 
by viruses. Identification of these host factors contributes to the potential target 
therapeutics122, 127 for the control of viral infection. As these cellular factors are of importance 
for cell functioning and they are mostly evolutionary conserved across the species. Thus, 
despite of high mutation rates in many viruses which helps them escape the immune system, 
one can target cell-specific host-factors to inhibit/reduce viral replication. Therefore, the 
identification of viral dependences on host factor provides us with the extensive details of 
viral life cycle along with the host-cell components exploited by them, which might be used 
for future therapeutics.  
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CHAPTER-2 
MATERIALS and METHODS 
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2.1 Materials 
 
2.1.1 Chemicals and Reagents 
All the chemicals were acquired by scientific reagents providers. 
 
Chemical       Company 
2-b mercaptoethanol      Sigma, Munich 
Brefeldin A       eBioscience 
Carboxyfluorescein Succinimidyl Ester (CFSE)  Invitrogen, Darmstadt 
Cell Lysing Solution      BD Bioscience, Heidelberg 
Citric Acid       Sigma, Munich 
DEPC-Treated water      ThermoFisher Scientific 
dNTPs        Promega 
DPBS w/o Mg2+, Ca2+     Pan Biotec, GmBH 
Ethanol       Merck 
Ethylenediaminetetracetic acid (EDTA)   Sigma, Munich 
Fetal Calf Serum (FCS)     Biochrom AG, Berlin 
Fluorescent Mounting medium    DAKO 
Formaldehyde        Sigma, Munich 
L-Glutamine        Sigma, Munich 
Lipopolysaccharides of Escherichia coli (LPS)  Sigma, Munich 
Methanol       Sigma, Munich 
Methylcellulose      Merck Fluka  
Penicillin-Streptomycin     Sigma, Munich 
Polyinosinic-polycytidylic acid (Poly I:C)   Sigma, Munich  
o-Phenylenediamine dihydrochloride    Sigma, Munich 
Saponin       Sigma, Munich 
Sodium Bicarbonate      Sigma, Munich 
Tissue Tek       Sakura 
Taq Polymerase      Promega 
TRIzol Reagent      ThermoFisher Scientific 
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2.1.2 Medium 
Reagent       Company 
Dulbecco’s Modified Eagle’s Medium (DMEM)  Pan Biotec GmBH 
Iscove’s Modified Dubelcco’s Medium (IMDM)  Sigma, Munich 
Very Low Endotoxin (VLE)-DMEM    Biochrom AG, Berlin 
 
2.1.3 Kits 
Reagent       Company 
IFN-a ELISA Kit      PBL  
QuantiTect Reverse Transcription Kit   Qiagen 
 
2.1.4 Antibodies 
Antibody       Company 
Anti-CD169 (CD274)      eBioscience 
Anti-B220       eBioscience 
Anti-CD11b       eBioscience 
Anti-CD11c       eBioscience 
Anti-CD3       eBioscience 
Anti-CD4       eBioscience 
Anti-CD8       eBioscience 
Anti-CD19       eBioscience 
Anti-CD90.2       eBioscience 
Anti-Cleaved Caspase-3     Abcam 
Anti-F4/80       eBioscience 
Anti-GFP       Abcam 
Anti-Gr-1 (clone RB6-8C5)     Bio X Cell 
Anti-IFNg       eBioscience 
Anti-LCMV-NP (VL4)     Lab produced 
Anti-Ly6C       eBioscience 
Anti-Ly6G (clone 1A8)     Bio X Cell 
Anti-mPDCA       eBioscience 
Anti-PDL1       eBioscience 
Anti-VSV-GP       Lab produced 
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Anti-Rabbit Cy5      Jackson ImmunoResearch 
Goat anti-Rabbit Biotin     Jackson ImmunoResearch 
Rabbit monoclonal Anti-Phospho B-Myb    Origene 
Streptavidin (Fluorescent labelled)    eBioscience 
 
2.1.4 Primers 
Name   Sequence/Catalog     Company 
LCMV-GP Forward CGA GCA TCA AAG CTG TGT ACA AT  Biomers 
LCMV-GP Reverse AAA AGG AAG CTG ACC AGT GCT AA  Biomers 
VSV-GP Forward TGA TAG TAC CGG AGG ATT GAC GAC Biomers 
VSV-GP Reverse CCT TGC AGT GAC ATG ACT GCT CTT  Biomers 
 
2.1.4a TaqMan Probes 
Name    Catalog   Company 
Mybl2    Mm00485340_m1  ThermoFisher Scientific 
Atp6ap2   Mm00510396_m1  ThermoFisher Scientific 
Atp6v0b   Mm01193846_g1  ThermoFisher Scientific 
Atp6v0d1   Mm00442649_m1  ThermoFisher Scientific 
Arcn    Mm00524375_m1  ThermoFisher Scientific 
Copb1    Mm00446330_m1  ThermoFisher Scientific 
Copa    Mm00550231_m1  ThermoFisher Scientific 
Mat2a    Mm00728688_s1  ThermoFisher Scientific 
Eif3a    Mm00468721_m1  ThermoFisher Scientific 
Eif3g    Mm00469383_m1  ThermoFisher Scientific 
Nop56    Mm00458467_m1  ThermoFisher Scientific 
MMP14   Mm00485054_m1  ThermoFisher Scientific 
MMP2    Mm00439498_m1  ThermoFisher Scientific 
MMP9    Mm00442991_m1  ThermoFisher Scientific 
PDGFß   Mm00440677_m1  ThermoFisher Scientific 
VEGFA   Mm00437306_m1  ThermoFisher Scientific 
VEGFB   Mm00442102_m1  ThermoFisher Scientific 
VEGFC   Mm00437310_m1  ThermoFisher Scientific 
FGFR    Mm00438930_m1  ThermoFisher Scientific 
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FGFR2   Mm01269930_m1  ThermoFisher Scientific 
FGFR3   Mm00433294_m1  ThermoFisher Scientific 
EGF    Mm00438696_m1  ThermoFisher Scientific 
ANGPT1   Mm00456503_m1  ThermoFisher Scientific 
SELL    Mm00441291_m1  ThermoFisher Scientific 
CCL5    Mm01302427_m1  ThermoFisher Scientific 
CXCL3   Mm01701838_m1  ThermoFisher Scientific 
Csf3    Mm00438334_m1  ThermoFisher Scientific 
CXCL15   Mm00441263_m1  ThermoFisher Scientific 
CXCL1   Mm04207460_m1  ThermoFisher Scientific 
Gapdh    Mm03302249_g1  ThermoFisher Scientific 
 
2.1.4b SYBR Green Probes 
Name    Catalog   Company 
IFNa4    QT01774353   Qiagen 
IFNß    QT00249662   Qiagen 
IRF7    QT00245266   Qiagen 
OAS1    QT01056048   Qiagen 
ISG15    QT02274335   Qiagen 
Ly6C    QT00247604   Qiagen 
CCR2    QT02276813   Qiagen 
CCL2    QT00167832   Qiagen 
 
2.1.5 Equipment 
Equipment       Company 
Cryostat CM 3050S      Leica 
ChemiDoc MP Imaging system    BioRad 
FLUOstar Omega ELISA Reader    BMG Labtech 
FACS Fortessa      Becton Dickinson (BD) 
Fluorescence Microscope HS BZ-9000   Keyence GmBH 
LightCycler 480 realtime PCR machine   Roche 
SP8 gSTED Confocal microscope    Leica 
Nanodrop        Peqlab 
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Thermocycler PCR machine     Applied Biosystems 
TissueLyser II       Qiagen 
Micro-centrifuge      Hettich 
Centrifuge 2210R      Eppendorf 
 
2.1.6 Plastic wares 
Items        Company 
1.5 ml tubes       Eppendorf 
2.0 ml         Eppendorf 
5 ml Polystyrene tubes     BD Falcon 
10 ml syringe       Braun 
15 ml Falcon tubes      Corning 
50 ml Falcon Tubes      Corning 
10µl Pipettes tips      STAR Labs 
200µl Pipettes Tips      STAR Labs 
1ml Pipettes Tips      STAR Labs 
5 ml Pipettes       Corning 
10 ml pipettes       Corning 
25 ml Pipettes       Corning 
70µ Cell strainer      BD  
6-well Plate       TPP 
24- well Plate       TPP 
96-well Plate       TPP 
MicroAmp 384-well Plate     Applied Biosystems 
Reservoirs       VWR 
Tissue-culture Flasks      TPP 
 
 
2.1.7 Cells: 
Various murine and human cells have been used in the present study. These cell line have 
been either purchased from companies or gifted from our collaborators. All cell lines were 
maintained mycoplasma free and grown in a humidified 37 oC chamber with 5% CO2.  
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Cell Lines  Source Cell-type   Company/Collaborator 
MCF-7  Human Breast carcinoma  ATCC 
MOPC   Murine Oropharyngeal carcinoma Dr. H.J. Lee, University of Iowa 
EL4-OVA  Murine Lymphoma   Dr. B. Huard, UMC, Geneva 
B16F10  Murine Melanoma   ATCC 
B16-OVA  Murine Melanoma   Prof. P. Knolle, TU, Munich 
MC38   Murine Colon carcinoma  Dr. B. Huard, UMC, Geneva 
SW480  Human Colon carcinoma  ATCC 
FaDu   Human Oropharyngeal carcinoma ATCC   
HepG2   Human Hematoma   ATCC 
HeLa   Human Cervix carcinoma  ATCC 
FHC-CRL183  Human Primary Colon cells  ATCC 
NBHE CC2540 Human Primary Bronchial Epithelial LONZA   
HRE CC2556  Human Primary Hepatocytes  LONZA   
NHEM C-12453 Human Primary Melanocytes  PromoCell 
 
2.1.8 Mice 
All the mice used in the study were maintained on the C57BL6/J background and housed in 
single ventilated cages under standard temperature and pressure conditions. All experiments 
done were authorized by Landesamt für Natur, Umwelt und Verbraucherschutz in Nordrhein 
Westfalen (Recklinghausen, Germany) and were performed under the German animal 
protection law.  
Besides C57BL6/J mice which were used as WT, multiple other mice have been used in this 
study. 
 
Cag+/- Mybl2fl/fl 
These mice have a cag promoter with cre recombinase fused with estrogen receptor (ER) 
gene and Mybl2 gene floxed on both prime ends with LoxP128. Upon induction with 
tamoxifen, CreER gets activated by dissociation of Hsp90 and translocate to nucleus. Cre 
recognizes LoxP sites and cleaves them excising the region flanked by them. This leads to 
deletion of the gene/gene functionality. These mice were used as Cag+ which when injected 
with tamoxifen leads to deletion of B-Myb and Cag- (control) which doesn’t lead to B-Myb 
deletion and acts as WT. 
Piyush	Sharma	 28	
	
 
Ifnar-/- mice 
These mice lack IFNa/b receptor and thus lacks IFN signaling129. These mice suffer from 
uncontrolled virus replication and eventually succumb to the infection 
 
Tcrb-/- mice 
Tcrb-/- mice are genetically engineered immunodeficient mice which lack the T cell receptor 
beta chain130.  
 
Vi10 ´ CD45.1 mice 
These mice bear a knock-in construct of VSV-neutralizing ab in the Ig locus. This in-turn 
produce VSV-specific BCR and thus results in rapid B-Cell response on VSV infection131. 
The Vi10 mice is further crossed with CD45.1 mice to produce a constitutive expression of 
CD45.1 on its lymphocytes. 
 
Tg7 Thy1.1 
These mice have knock-in of gene coding for VSV glycoprotein peptide. Thus, these mice 
express MHC-II TCR specific for VSV-GP132. These mice were then crossed with Thy1.1 
mice to exchange the expression of CD90.2 to CD90.1. 
 
Map3k14aly/aly 
These mice carry a mutated aly gene resulting in absence of well-developed lymphoid 
follicles in spleen and distorted/absence of cortical-medullary regions in thymus. The mutant 
homozygotes display deficiency in both humoral and cell-mediated immune response133.  
 
Jh-/- 
These mice harbors deletion of JH segments and intron enhancer in IgH locus. This leads to 
complete absence of functional B-cells134. 
 
Rag1-/- 
These mice are generated by introducing a mutation in Rag1 gene which renders it non-
functional. These mice fail to perform V(D)J recombination during T and B-cell development 
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and differentiation. Therefore, they have small lymphoid organs devoid of mature T and B 
lymphocytes32. 
 
Irf3-/-´ Irf7-/-  
These mice lack the gene expression and function of Irf3 and Irf7 gene, resulting in the 
absence of interferon induction135. Lack of interferon signaling and pathway leads to the 
uncontrolled virus replication and defective immune response.  
 
2.2 Methods 
 
2.2.1 Bone Marrow derived macrophage and dendritic cell generation: 
Mice were sacrificed by cervical dislocation. Abdomen and hind legs were sterilized, 
afterwards femur and tibia was isolated. After removing all muscle tissue, bones were stored 
in cold PBS. Bones were then disinfected with 70% ethanol for 5 min and then transferred to 
ice-cold PBS. After thorough cleaning of the bone, epiphyses were carefully cut from both 
ends. Bone marrow was then flushed from one end with cold VLE-DMEM via 24G syringe 
into a 50ml falcon and then centrifuged at 1400 rpm for 5 min at 4°C. Supernatant was 
discarded and cells were lysed with erythrocyte lysis buffer (ELB) for 2 min at RT. Lysis was 
stopped with 10%FCS (LPS free) containing VLE-DMEM and passed through a cell strainer. 
The cells were then again centrifuged at 1400 rpm for 5 min at 4°C. Supernatant was 
discarded and cells were re-suspended in 5 ml VLE-DMEM. Cell number was determined 
using haemocytometer and were plated in 10mm dishes at density of 3x106 cells in MCSF 
containing media for macrophages and GMCSF containing media for dendritic cells, and kept 
at 37°C. At day 3, 10 ml of fresh media was added and at day 6 complete media was changed 
with fresh media. Cells were harvested at day 6 and plated into 6/24 well plates for 
experiment with appropriate medium. 
Reagents: 
Macrophage Medium     Dendritic Cell medium 
VLE-DMEM (450ml)      VLE-DMEM (450ml) 
20% (v/v) M-CSF      2% (v/v) GMCSF 
10% FCS (LPS free)      10% FCS (LPS free) 
0.1% (v/v) 50mM ß-me     0.1% (v/v) 50mM ß-me 
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Erythrocyte Lysis Buffer (ERB) 
0.5M NH4Cl2 
10mM KHCO3 
0.1mM EDTA (pH 7.2) 
 
2.2.2 B-myb FACS staining: 
 For detection of phospho-B-Myb, spleen samples were dissociated in 1ml chilled 
phosphate-buffered saline(PBS). 100ul of each sample was then stained with α-CD169, α-
CD8, α-Ly6C, α-Ly6G, α-CD4 and B220 at 4o C for 30 min, samples were then washed with 
PBS and fixed with 10% PFA for 10 min and then permeabilized with 2% saponin/PBS for 
10 min at RT. After permeabilization, samples were blocked with 2% mouse serum/PBS for 
20 min, stained with phospho-B-Myb for 60 min followed by α-Rb IgG biotin for 30 min and 
then FITC-streptavidin for 30 min at 4oC.  
 
2.2.3 VSV and LCMV Production 
 VSV virus and LCMV virus (WE and Docile) were propagated on BHK-21 cells and 
L929 cells respectively.  The cells were grown in DMEM medium containing 10% FCS, 1% 
penicillin, streptomycin (P/S) and L-glutamine (Glut) at 37oC until 70% confluency is 
reached. Then cells were infected with either VSV or LCMV at a multiplicity of infection 
(MOI) of 0.0001 in a total volume of 5 ml and incubated for 1 hour at 37oC.  25ml of the 
same DMEM medium were added and incubated for 48 hours. Medium was collected and 
subjected to centrifugation at 3000 rpm at 4oC to remove large debris. Supernatant was then 
collected in cyro-tubes and stored at -80°C. The virus was administrated into the animals by 
intravenous (i.v.) injection. 
 
2.2.4 VSV Plaque Assay: 
 For detection of VSV viral titers, assay was done using vero cells. Number of samples 
were determined and accordingly 24-well plates were taken. Vero cells were plated as 3x104 
cells/well and incubated at 37 oC incubator overnight. Samples were prepared and titrated as 
explained in LCMV plaque assay. 24-well plates containing confluent monolayer of vero 
cells were taken out and media was discarded. Titrated sample were then added to the plates 
and incubated for 2 hours at 37 oC after which overlay was added to the wells and again 
incubated at 37 oC for 24 hours or until plaques were visible under the microscope.  
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2.2.4a Staining:  
Medium was discarded from the plates. Crystal violet staining solution was added to the 
plates and incubated at RT for 20-30 min. Plates were then washed with running water and 
dried inverted on paper towels. Clear plaques were counted and analyzed accordingly. 
 
Reagents: 
Overlay Medium     Crystal Violet Staining solution 
VLE-DMEM (450ml)     VLE-DMEM (450ml) 
20% (v/v) M-CSF     3% (v/v) GMCSF 
10% FCS (LPS free)     10% FCS (LPS free) 
0.1% (v/v) 50mM ß-me    0.1% (v/v) 50mM ß-me 
 
 
2.2.5 LCMV Titer assay: 
 For detection of viral titers in organs and cell cultures, plaque assay was done with 
MC57 cells. The organs were homogenized in tissuelyser and centrifuged at 1500 rpm for 10 
min. Supernatant was then titrated as 1:3 over 12 rows in a 12-well plate in 2% FCS/DMEM 
supplemented with 1% penstrep and glutamine. Titrated samples were then plated in 24 well 
plates along with 200µl of MC57 cells at the density of 9x105 cells/ml. Plates were kept at 37 
oC for 3 hours and then overlay was added and incubated again for 72 hours at 37 oC. 
 
2.2.5a Staining:  
Plates content was discarded and plates were incubated at RT with 4%(v/v) formaldehyde for 
30 min. Formaldehyde was then replaced with 1%(v/v) Triton-X and incubated for 20 min at 
RT. Plates were then washed with PBS twice and blocking solution of 10% (v/v) FCS in PBS 
was added and incubated for 60 min at RT. Primary antibody VL4 was diluted in 1% (v/v) 
FCS/PBS and was added as 200µl/well and incubated for 60 min at RT. After washing twice 
in PBS, secondary antibody HRP linked	α- rat IgG was diluted in 1% (v/v) FCS/PBS and was 
added as 200µl/well and kept at RT for 60 min. Plates were again washed with PBS twice 
and staining solution was added and incubated for 20-30 min at RT. Once the plaques were 
visible, plates were washed with water and plaques were counted. 
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Reagents: 
Overlay Medium        
50% (v/v) 2x IMDM (pH 7.4)    
50% (v/v) 2% Methyl-cellulose   
  
Staining Solution for LCMV    
25%(v/v) 0.2M Na2HPO4     
25% (v/v) 0.1M Citric acid     
20 mg o-Phenylenediamine dihydrochloride   
50 µl of 30% H2O2      
50 ml ddH20 
 
2.2.6 Immunohistochemistry: 
 For the detection of cellular protein, immunohistochemistry was performed. Organs 
were harvested and stored immediately in histological tubes with tissue-tek and put in liquid 
nitrogen. Embedded tissues were then taken to cryotome and mounted on loading discs. 
Tissue slices were then cut at 8µ in size on glass slides. Slides were stored at 4 oC until use. 
All the histological cutting was done below -10 oC.  
 
2.2.6a Immunostaining:  
Slides were put in acetone for 10 min and then dried for few seconds. Tissue sections were 
then outlined with an oil-pen and let it dry for few seconds. Samples were then blocked with 
2% FCS/PBS for 10 min at RT and then mounted on staining chamber. Primary antibodies 
were added diluted in 2% FCS/PBS on to the samples and incubated for 60 min at RT. Then 
samples were washed with 2% FCS/PBS and appropriate secondary antibody and then 
tertiary (if required) was added and again incubated for 60 min at RT. Samples were then 
washed again with 2% FCS/PBS and mounted with DAKO mounting solution and stored at 
4oC until microscopy was performed.  
 
2.2.6b B-Myb immunohistostaining: 
Slides were brought to RT and then fixed with 10% NBF. Tissue sections were then marked 
with oil-pen and were blocked with 2% FCS/PBS for 10 min at RT. After blocking, slides 
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were mounted on staining chamber and primary antibody α-phsopho B-Myb was added in a 
dilution of 1:100 in 2% FCS/0.5% saponin in PBS. Slides were incubated for 60 min at RT. 
Slides were washed and then exposed to secondary antibody PE labelled α-Rb IgG in a 
dilution of 1:200 in 2% FCS/PBS for 30 min at RT. Slides were washed, mounted with 
DAKO and stored at 4oC until microscopy. 
 
2.2.7 RNA isolation: 
 RNA was isolated using TRIzol (Thermo Fisher) according to the manufacturer’s 
protocol. Organs were homogenized in 1ml TRIzol and kept at RT for 10 min. 200µl of 
chloroform was added to each sample and mixed thoroughly by inverting the tubes multiple 
times. Samples were then centrifuged at 13000 rpm for 15 min at 4oC. Upper aqueous layer 
was then collected in a separate tube and equal volume of iso-propanol was added and mixed 
thoroughly. Samples were then incubated in ice for 10 min and then centrifuged at 13000 rpm 
for 15 min at 4 oC. Next, samples were washed twice with 70% ethanol in DEPC water by 
centrifugation for 10 min each. Supernatant was taken out via vacuum pump and samples 
were air dried further for 5-10 min. Samples were then dissolved in DEPC water at 56 oC for 
10 min, quantified using nanodrop and then stored at -20 oC. 
 
2.2.8 cDNA Synthesis: 
 cDNA was synthesized from the isolated RNA samples using Qiagen QuantiTect 
Reverse Transcription kit as per manufacturer’s protocol. Briefly, 1000ng of RNA was taken 
and any DNA contamination was removed by gDNA wipeout reagent and then a mastermix 
of QuantiTect reverse transcriptase, RT-buffer and RT-primer mix was added and incubated 
at 42 oC for 30 min. Enzyme reaction was then inactivated by heating the samples at 92 oC 
for 2 min. Samples were stored at -20 oC until further use. 
 
2.2.9 Intracellular cytokine staining: 
 ICS is performed to detect the cytokine levels produced by T-cells. Organs were 
harvested and smashed in DMEM. Cells were then transferred to 96 well plate and washed 
again with ice-cold DMEM by centrifugation as 1400 rpm for 5 min at 4 oC. 100µl of vial 
peptide was added for stimulation of T-cells (VSV peptide: p52 for CD8+ and p8 for CD4+ T-
cells; LCMV peptide: gp33 for CD8+ and gp64 for CD4+ T-cells) in a dilution of 1:200 in 2% 
FCS/DMEM and incubated at 37 oC for 1 hour. 20µl BFA was then added to each sample in a 
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dilution of 1:200 in 2% FCS/DMEM with 1% P/S and Glut and incubated at 37 oC for 5 
hours. Samples were then washed with FACS buffer and fluorescent antibodies against CD8 
and CD4 diluted as 1:100 in FACS buffer were added to each sample and incubated at 4 oC 
for 30 min. After washing with FACS buffer, samples were fixed with 2% (v/v) formalin in 
FACS buffer for 10 min at RT and then washed again followed by permeabilization with 1% 
saponin (v/v) in FACS buffer for 10 min at RT. Antibody cocktail was of fluorescent a-IFNg 
and a-TNFa in 1% saponin/FACS buffer and incubated at 4 oC for 30 min. Samples were 
then finally washed with FACS buffer and analyzed. 
 
2.2.10 Cell culture 
 All the cells were maintained in humidified incubator at 37 oC with 5% CO2 with the 
desired growth medium. Cells were split using trypsin treatment for 2-4 minutes at 37 oC, 
which then was inactivated by FCS containing medium. Different medium was used for 
different cell lines as per provider’s protocol.  
 
2.2.11 RT-PCR 
 Gene expression was performed using Roche LightCycler 480 with either SYBR-
Green or Taqman probes. For analysis, the observed expression levels of all target genes 
were normalized to either GAPDH or 18s rRNA expression (ΔCt). Gene expression values 
were then calculated based on the ΔΔCt method. Relative quantities (RQ) were determined 
with the equation: RQ=2^ (-ΔΔCt). The values were wither plotted multiplied to a constant or 
with-relative to the non-infected control.  
 
2.2.12 siRNA knockdown 
 siRNA complexes were obtained from Origene for the transient knockdown in cells. 
20µM stock of each siRNA duplex was made by adding 100µl of the RNase-free buffer and 
heated at 72 oC for 2 min and then cooled down to RT. Working stocks of 5µM of each 
duplex were made and stored in aliquots at -80 oC. 
Transfection with siRNA was done in MCF-7 cells. 2x105 cells /well were plated in a 6-well 
plate and grown at 37 oC until they reach 50-60% confluency. The medium was then replaced 
with 2.38 ml of fresh medium. Working siRNA complex was prepared by adding 5µl from 
working siRNA stock to 95µl of serum and antibiotic-free DMEM along with 20µl of 
HiperFect and mixed by vortexing. The mixture was then incubated for 10 min at RT and 
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added to the cells dropwise with constant shaking of plates. The final concentration of siRNA 
is 10 nM.  
 
2.2.13 In-vivo siRNA knockdown 
In-vivo siRNA kit was purchased from Ambion, Thermo Fisher Scientific. The scrambled 
control and B-Myb specific siRNA was prepared in invivofectamine (Thermo Fisher 
Scientific) as per manufacturer’s protocol. Prepared siRNA complex was injected 
intravenously. 
 
2.2.14 In-vivo cell depletion 
 Depletion of in-vivo was carried out by injecting the cell-specific antibodies. For NK-
cell depletion, 50 µg of NK1.1 (produced in-house) in injected i.p. at day -10 and -3. For 
collective depletion of Ly6C+ and Ly6G+ cells Gr-1 antibody was given whereas for depletion 
of specifically Ly6G+ cells, aLy6G (500 µg) was given. Both these antibodies were given i.p 
thrice at day -2, 2 and 7.  
 
2.2.15 Morphometric analysis of tumor vessels and hypoxia 
 The morphometric analysis was carried out by analysis of CD31 staining on 
consecutive cryosections of tumors. MVD was calculated as number of vessels per tumor 
area in top, middle and bottom section of tumor. Vessel-to –vessel distance was calculated by 
using the middle sections of the three sections (upper, middle and bottom) by Cell P software 
(Olympus, Germany).  For hypoxic tumor areas analysis, Pimonidazole was injected 30 min 
prior to killing of mice. Hypoxic areas were detected by formation of pimonidazole adducts, 
and sections were stained with hydroxyprobe-1 Plus Kit. 
 
2.2.16 SDS- electrophoresis 
 SDS-gel electrophoresis was carried for the protein expression analysis using BioRad 
Mini PROTEAN system. 10% resolving poly-acrylamide gel was cast in glass plates and left 
for 30-40 minutes at RT for polymerization. Iso-propanol was used as overlay to keep the gel 
from drying out. Then 4% poly-acrylamide stacking gel was made and cast on top of the 
resolving gel with combs inserted. The gel was allowed to polymerize for 20-30 min at RT. 
Gel cast was removed and put it to the loading chamber along with SDS-running buffer. 
Samples were pre-heated at 95 oC before loading. Equal amount of protein was loaded in the 
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gel and was initially electrophoresis was performed at 80 V for complete stacking of proteins. 
Once the proteins are stacked, voltage was turned up to 100 V to separate the proteins 
according to their molecular weight. Samples were then run up to desired molecular weight 
and processed further.  
Reagents 
10x SDS-Running Buffer 
30 gm Tris base 
144 gm Glycine 
10 gm SDS 
1000 ml ddH20  
 
     10% Resolving Gel  3.5% Stacking Gel 
30% Acrylamide    3.3 ml    0.45 ml 
1M Tris-Cl (pH 8.0)    3.6 ml     - 
1M Tris-Cl (pH 6.8)    -    0.38 ml 
10% SDS (w/v)    98 µl    30 µl 
10% APS (w/v)    98 µl    30 µl 
TEMED     8.1µl    5 µl 
 
2.2.17 Western blotting 
 Western blotting is done to detect the presence and to quantify the protein in sample. 
Proteins were transferred using wet blot method. Polyacrylamide gel was taken out of the 
electrophoretic chamber and transferred to western transfer buffer after the removal of 
stacking gel along with nitrocellulose membrane. Western blot chamber cassette was then 
arranged from anode to cathode; first with two whatman paper soaked in western transfer 
buffer followed by the polyacrylamide gel containing proteins. Then wet nitrocellulose 
membrane was put carefully avoiding any bubbles and finally whatman papers were put on 
top. The stack was pressed with botting roller gently to remove any trapped air and cassette 
was closed. The blotting cassette was then transferred to the chamber containing ice-cold 
western transfer buffer. Ice pack was added to the chamber in order to maintain the 
temperature of the buffer during transfer. Transfer was done as 90 V for 1.5 hours. After 
transfer, membrane was carefully taken out and blocked with blocking buffer for 1 hour at 
RT to avoid non-specific binding of antibodies. Then incubation with primary antibody was 
done as 1:1000 dilution of the desired antibody in blocking buffer at 4 oC on a shaker 
overnight. Next day the membrane was washed thrice for 5 min each with 0.05 % Tween-
20/PBS (PBS-T) and incubated with HRP-linked secondary antibody diluted in blocking 
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buffer for 1 hour at RT on shaker. The blots were then washed with PBS-T thrice for 10 min 
each and were finally stored in PBS.  
DEVELOPMENT OF WESTERN BLOTS: Blots were incubated with thermo scientific 
femto chemiluminescent reagents for detection of phospho protein and with thermo scientific 
chemiluminescent reagents for total proteins for 5 min at RT. Blots were then developed and 
photographed using BioRad ChemiDoc.  
Reagents 
Transfer Buffer (10x) 1x Transfer buffer     
30 gm Tris   10x transfer Buffer (100 ml)    
144 gm Glycine  Methanol (200 ml)    
ddH2O (1000 ml)  ddH2O (700 ml) 
     
PBS-T       Blocking Buffer 
1x PBS      Non-fat dried milk (5% w/v) 
0.05% Tween-20     PBS-T  
 
2.2.16 FACS  
 FACS acquisition was performed on BD FACS Fortessa and analysis was performed 
on FlowJo 10. Organs were harvested and then crushed in cold PBS. Cells were collected 
after washing with PBS once in a BD FACS tube. Antibody cocktail was made with desired 
antibodies in FACS buffer in a dilution of 1:100/ sample. Samples were then incubated at 4 
oC for 30 min and then washed with FACS buffer via centrifugation at 1500rpm for 5 min. 
Cells were re-suspended in FACS buffer and were analyzed.  
 Virus-Specific CD8+ T-cell staining.  
Samples were taken in FACS tubes and were incubated with fluorescent Labelled (APC) 
GP33 tetramer for 15 min at 37 oC. Cocktail of CD8 along with other desired markers was 
made in FACS buffer as 1:100/sample and added to each sample. Samples were then 
incubated at 4 oC for 30 min and then washed afterwards with FACS buffer. In case of blood 
samples, erythrocytes were lysed with BD Cell Lysing buffer for 7 min and then washed with 
FACS buffer. Samples were then re-suspended in FACS buffer and were analyzed.  
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2.2.17 Genotyping 
 In order to determine the transgenic state of the mice, genotyping was performed. 
Mice were ear-marked and 2-4 mm of tail was cut and put into 600 µl digestion buffer. 
Proteinase-K was then added at the concentration of 20 ug/ml. Samples were then incubated 
at 56oC till the tails were dissolved properly. Samples were then spun down to collect tail 
hairs and supernatant was transferred to a fresh tube. Equal amount of iso-propanol was 
added to the samples and mixed properly. Samples were then centrifuged at 12000 rpm for 10 
min at 4 oC and then washed twice with 70% ethanol. Samples were then air-dried and 
dissolved in DEPC water at 60 oC, quantified and stored at 4 oC. For genotyping PCR, 50-100 
ng of DNA was taken and added with the optimized concentration of PCR mix and primers 
and then run in PCR machine. Amplified samples were then visualized by agarose gel 
electrophoresis. 
 
2.2.18 Statistical Analysis 
 All the results were analyzed from minimum of three biological replicates (n = 3), 
unless indicated otherwise. The level of significance was calculated using the Student's t-
test. In case of presence of more than two groups, 1-way ANOVA followed by a Tukey 
post-test was carried out. Survival analysis was compared with log-rank (Mantel-Cox) tests. 
All the data are presented as mean ± S.E.M. Observed p-values are indicated as "*" (p ≤ 
0.05), "**" (p ≤ 0.01), "***" (p ≤ 0.001), "****" (p ≤ 0.0001). 
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CHAPTER-3 
RESULTS 
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RESULT 1: B-Myb is a major host factor for viral replication 
3.1.1 Active VSV replication induces B-Myb phosphorylation. 
For certain viruses such as VSV, early virus replication occurs in CD169+ 
macrophages also known as marginal zone macrophages which are present in the spleen15. 
Upon infection, virus is taken up via APCs into the spleen from blood stream. The spleen is 
an important site for viral processing due to presence of T and B-cells in white pulp 
surrounded by APCs and it represents an ideal special layout of cells for effective processing 
of viral antigens and immune activation. Upon virus uptake, many genes are up-regulated by 
the host in the marginal zone macrophages of the spleen in order to facilitate early viral 
replication. 
To address the activation of B-Myb during VSV replication, we infected C57BL6/J 
(WT) mice with 2x108 PFU VSV intravenously. Mice were sacrificed after 7 hours of 
infection and spleen were harvested for immunohistochemistry and FACS for detection of 
phospho-B-Myb (p-B-Myb). We found out that the B-Myb is phosphorylated specifically in 
VSV replicating CD169+ macrophages (Fig. 6A). To further verify whether phosphorylation 
of B-Myb is specific to infected CD169+ macrophages on early VSV replication, we 
performed confocal analysis of histological samples as well as FACS evaluation of phospho-
B-Myb expression. In confocal analysis, we demonstrated that indeed phosphorylation of B-
Myb occurs specifically in CD169+ macrophages (Fig. 6B). Next, we performed FACS 
analysis in different immune cell types present in the spleen to quantify p-B-Myb expression. 
The analysis revealed distinct and significant upregulation of p-B-Myb expression in infected 
CD169+ macrophages compared to naïve, whereas other infected cells expressed the same 
amount of p-B-Myb compared to their naïve counterparts (Fig. 6C, Fig. A1). Next, we 
wondered whether active VSV replication is indeed required for B-Myb phosphorylation, so 
we inactivated VSV under UV-light twice for duration of 5 min each and infected WT mice 
with 2x108 PFU. Spleens were harvested for immunohistochemical analysis, which showed 
no phosphorylation of B-Myb upon UV-inactivated VSV (Fig 6A). We also wondered 
whether other molecules that are activated along with B-Myb are also involved in VSV 
replication. One such molecule is CyclinD1, which is activated alongside of B-Myb. Upon 
analysis, we found out that there was no effect on the expression of Cyclin-D1 during VSV 
infection (Fig. 6D).  
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Figure 6: VSV replication phosphorylates B-Myb in CD169+ macrophages 
A: Immunohistochemistry of phospho B-Myb of spleen sections from C57BL6/J mice 
infected with 2x108 PFU VSV, 8 hrs p.i.(n=6) B: Confocal analysis of spleen of C57BL/6J 
mice infected with 2x108 PFU VSV, 8 hrs p.i.(n=6). C: FACS histograms and quantification 
analysis of phospho-B-Myb in different cells from spleen of C57BL/6J mice infected with 
2x108 PFU VSV, 8 hrs p.i.(n=5). D: Immunohistochemistry of phospho B-Myb and cyclin 
D1 of spleen sections from C57BL6/J mice infected with 2x108 PFU VSV, 8 hrs p.i.(n=4) 
 
3.1.2 In-vitro and in-vivo knockdown of B-Myb reduces virus replication. 
Next, we checked whether the knockdown of B-Myb has functional consequences on 
virus replication. We performed siRNA knockdown of B-Myb in-vitro and in-vivo.  
For in-vitro analysis, we used origene siRNA directed against human B-Myb and performed 
knockdown in MCF7 breast cancer cells. The cells were transfected and were collected for 
western blot analysis for 24 and 48 hours post-transfection. Protein analysis revealed the 
level of B-Myb was robustly reduced 24 and 48 hours post transfection (Fig. 7A). As B-Myb 
is a crucial cell proliferation regulation transcription factor, we checked whether the transient 
knockdown induced apoptosis via propidium-iodide staining. We found no significant 
apoptosis when compared to scrambled control with one siRNA (Fig. 7A, right panel). Next, 
we checked for virus replication using LCMV and VSV as viral models. MCF7 cells were 
grown in 24 well plates and on cover-slips and were then transfected with one control and the 
non-apoptotic inducting B-Myb directed siRNA. The cells were then infected with an MOI 
1.0 of both viruses 24 hours post-transfection. Supernatant was taken at 24 and 48 hours post 
infection of LCMV and coverslips were processed for immunocytochemistry (ICC) for 
detection of LCMV-NP and VSV-GP after 24 and 7 hours respectively. Upon analysis of 
D 
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infective viral titers after LCMV infection via plaque assay, we found significant reduction in 
the LCMV viral titers in B-Myb knockdown cells as compared to scrambled controls (Fig. 
7B). This showed that B-Myb has an impact on virus replication and the production of active 
viral particles. ICC analysis confirmed this as we found reduced LCMV-NP and VSV-GP 
expression in B-Myb knockdown cells (Fig. 7C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Transient knockdown of B-Myb abrogates LCMV and VSV replication in-
vitro 
A: representative immunoblot of control and B-Myb siRNA transfected MCF7, 24 and 48 
hours post transfection (n=3-4) and Pre-G1analysis of MCF7 cells transfected with control 
and 2 independent siRNA (n=3) B: LCMV infective viral titers from MCF7 cells transfected 
with control and B-Myb siRNA, 24 hrs p.i.(n=5). C: Immunocytochemistry analysis of 
LCMV-NP and VSV-GP from LCMV and VSV MOI 1.0 infected, control and B-Myb 
specific siRNA treated MCF7 cells, 24 hrs (LCMV) 7hrs (VSV) p.i. (n=3).  
 
Next, to further test that B-Myb dependent virus replication is not limited to a specific cell 
type but rather a global phenomenon we used ambion in-vivo siRNA technology to 
knockdown B-Myb specifically in liver hepatocytes. This siRNA is specifically designed to 
A 
B C 
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target hepatocytes when injected intravenously (Fig. 8A). VSV, as discussed earlier is a 
cytolytic virus and interferon responsive. In a control scenario, when infected with VSV and 
immune response is launched and the virus is controlled with in spleen with little or no virus 
escape to vital organs. However, when macrophages are depleted and then infected, VSV is 
not controlled in the spleen and escapes to liver and other vital organs. We used this strategy 
in this experiment. First the mice were treated with in-vivo control and B-Myb directed 
siRNA intravenously and 12 hours later treated with clodronate-liposomes to deplete 
macrophages from the host. The mice were then infected with 2x106 VSV, and livers were 
harvested for immunohistochemistry and RNA analysis 18 hours post infection. Analysis 
revealed severe liver damage in scrambled control siRNA treated mice as compared to B-
Myb siRNA treated (Fig. 8B). This correlates with increased viral replication in control mice 
in histological analysis (Fig. 8C). Taken together, we showed that B-Myb depletion abrogates 
virus replication in-vitro and in-vivo and the observed phenomenon is not cell specific. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8: In-vivo liver depletion of B-Myb reduces VSV replication and damage in liver 
A: Quantitative mRNA analysis of B-Myb from liver of clodronate treated C57BL6/J mice 
transfected with Ambion in-vivo control and B-Myb specific siRNA, infected with 2x106 
PFU VSV, 18 hours p.i. (n=4) B: Serum alanine-aminotransferase (ALT) levels of clodronate 
treated C57BL6/J mice transfected with Ambion in-vivo control and B-Myb specific siRNA, 
A B 
C 
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infected with 2x106 PFU VSV, 18 hours p.i. (n=5) C: Immunohistochemistry and H&E 
analysis of VSV-GP from 2x106 PFU VSV infected, control and B-Myb specific siRNA 
treated C57BL6/J mice (n=5).  
 
3.1.3 B-Myb depletion abrogates VSV replication in-vivo. 
To study the role of B-Myb in VSV infection, we made use of tamoxifen induced 
mouse model in which the B-Myb allele is floxed. This leads to excision of B-Myb when 
tamoxifen is administered. In the control mice, the absence of the Cag promoter ensures that 
any non-specific effects of tamoxifen treatment are taken into account (Cag-Mybl2fl/fl control 
mice), whereas in the B-Myb conditional transgenic mice, Cag promoter is present at the start 
of B-Myb allele denoted as Cag+Mybl2fl/fl (B-Myb transgenic mice).  
 We optimized the tamoxifen dosage for knockdown of B-Myb. Optimized dose is 
obtained at 4mg/mouse, injected intra-peritonealy for three consecutive days. The mice were 
left for recombination for 48 hours and then used for experimentation (Fig. 9A).  RT-PCR 
analysis revealed that B-Myb is reduced by >60% in spleen and 80% in bone marrow after 
tamoxifen treatment (Fig. 9B). As B-myb depletion is also known to induce apoptosis90, we 
checked if our dosage of tamoxifen is inducing apoptosis in mice spleen. Both the control 
Cag-Mybl2fl/fl and transgenic Cag+Mybl2fl/fl mice were treated with tamoxifen and sacrificed 
2 days after last treatment. Spleen samples were analyzed for cleaved caspase-3 expression 
via immunohistochemistry showing no difference in the in the expression of the same n both 
control and B-Myb deficient mice (Fig. 9C). 
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Figure 9: In-vivo depletion of B-Myb via tamoxifen  
A: Experimental schematic of tamoxifen treatment for B-Myb depletion. B: Quantitaive 
mRNA analysis of B-Myb from spleen and bone marrow of Cag-Mybl2fl/fl and Cag+Mybl2fl/fl 
treated with tamoxifen (n= 3-5) C: Immunohistochemistry analysis of cleaved caspase-3 from 
tamoxifen Cag-Mybl2fl/fl and Cag+Mybl2fl/fl mice (n=4-5).  
 
Further, to determine whether the depletion of B-Myb has any effect on early virus 
replication, we treated control Cag-Mybl2fl/fl and transgenic Cag+Mybl2fl/fl mice with 2x108 
PFU VSV and sacrificed them 8 hour post infection. Spleen was harvested for 
immunohistology, viral titers and RNA analysis. Immunohistological analysis revealed 
significantly reduced virus replication in CD169+ macrophages (Fig. 10A) which is also 
reflected in reduced infective viral titers in B-Myb depleted mice (Fig. 10B). Further analysis 
confirmed significantly diminished VSV replication at the transcription level (Fig. 10C). 
Tamoxifen is an established drug which is used in cancer therapy136. Reports have also shown 
effects of tamoxifen in regulating viral replication in-vitro137, 138. To exclude any effects of 
tamoxifen on VSV replication, we treated WT mice with corn oil and tamoxifen and infected 
them with 2x108 PFU VSV. Mice were then sacrificed 8 hours later and analyzed for 
infective viral titers. Results showed no effect of tamoxifen on VSV titers between both 
groups (Fig. 10D).  Collectively, we show here that B-Myb plays an important role in 
ensuring early/initial VSV replication in CD169+ macrophages. 
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Figure 10: In-vivo B-Myb depletion abrogates VSV replication 
A: Immunofluorescence of spleen from tamoxifen treated Cag-Mybl2fl/fl and Cag+Mybl2fl/fl 
mice infected with 2x108 PFU VSV, 8 hours p.i. (n=6) B: Infective VSV titers from spleen of 
tamoxifen treats Cag-Mybl2fl/fl and Cag+Mybl2fl/fl mice infected with 2x108 PFU VSV, 8 
hours p.i. (n=5-6) C: Quantitative mRNA analysis of VSV-GP from tamoxifen treated Cag-
Mybl2fl/fl and Cag+Mybl2fl/fl mice infected with 2x108 PFU VSV, 8 hours p.i. (n=3-4). D: 
Infective VSV titers of control mice treated with or without tamoxifen, infected with 2x108 
PFU VSV, 8 hours p.i. (n=4-5). 
 
3.1.4 Effect of B-Myb deficiency on interferon responses. 
Interferon is a key player in antiviral defenses, especially Type-I interferon. Type-I 
interferon which includes IFN-a and b are known to be potent antiviral cytokines and also 
modulators of adaptive immune responses139. Viral replication in CD169+ macrophages is 
essential to initiate antiviral response as well as IFN-I production. In previous results, we 
showed that B-Myb deficiency impairs VSV replication. Also, VSV is known to be a highly 
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interferon responsive virus129 and thus tends to abrogates it for its successful replication140. 
Therefore, we checked for IFN-I induction in control and B-Myb deficient mice after 2x108 
PFU VSV infection. We found significantly lower IFN-I production in B-Myb deficient mice 
(Fig. 11A). To correlate the reduced interferon production with the observed effect of virus 
replication, we analyzed interferon-stimulated genes (ISGs) in the same experimental settings 
via RT-PCR. Results showed significant reduction in the gene expression level of the ISGs 
(Fig. 11B). The reduced IFN-I production and ISGs gene expression is a direct effect of 
reduced early VSV replication in CD169+ macrophages. 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: Reduced IFN response results from abrogated VSV replication 
A: Quantification of IFN-a in serum of tamoxifen treated Cag-Mybl2fl/fl and 
Cag+Mybl2fl/fl mice infected with 2x108 PFU VSV, 8 hours p.i. (n=5-6) B: Quantitative 
mRNA analysis of interferon induced genes from spleen of tamoxifen treated Cag-Mybl2fl/fl 
and Cag+Mybl2fl/fl mice infected with 2x108 PFU VSV, 8 hrs p.i. (n= 3). 
 
  Next, considering B-Myb is an important transcription factor, we checked whether B-
Myb deficiency itself have any effect on the immune signature of the cell with the use of 
immune stimulants such as LPS and Poly I:C. LPS is a lipopolysaccharide, which is 
expressed on the cell wall of gram-negative bacteria. LPS is recognized as PAMPs by PRRs 
and by TLRs141, 142. LPS forms a complex with LPS-binding protein (LBP) which further 
binds to CD14 which is either available in blood plasma or bound to the cell surface. The 
immune activation by LPS is mediated via its binding to TLR4143, 144, which includes 
activation of Nf-kB, ERK1/2, SAPK/JNK pathways.  Poly I:C is a synthetic analog of 
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dsRNA, which mimic the molecular patterns associated with viral infection. As it has been 
shown that dsRNA is been recognized by TLR3145, poly I:C acts via two ways once 
recognized by PRRs; endocytosed poly I:C activates TLR3 while cytosolic one activates 
RIG-I/MDA-5. Activation by poly I:C results in the induction of IL-12 and type-I IFNs 
which in-turn enhance the T and B cell immunity. Poly I:C has been reported to be used as an 
adjuvant as it also improves MHC-II expression and antigen cross-presentation146. 
  For this experiment, we generated bone marrow derived macrophages (BMDM) and 
dendritic cells (BMDC) and treated then with 7.5µM and 5µM 4-hydroxy tamoxifen for 48 
hours respectively. At first, we compared ISG expression in between VSV infection and other 
immune stimulants LPS and Poly I:C. Upon mRNA expression analysis, we found no effect 
of B-Myb deficiency on the immune signature in case of LPS and Poly I:C, whereas when 
infected with VSV, the expression of evaluated ISGs was significantly less (Fig. 12A). Next, 
we analyzed the phosphorylation status of up-stream molecules of immune-regulation 
pathways. We treated BMDC with LPS in a time dependent manner and Poly I:C for 7 hours 
and harvested for western blot analysis. Western blot was done for total Nf-kB p102, Nf-kB 
p65, iKKb and their phosphorylated forms. Analysis shows no significant difference in the 
activation of these molecules in B-Myb deficient BMDC when compared to control BMDC 
with both Poly I:C (Fig. 12B) and LPS (Fig. 12C) treatment. Taken all together, we showed 
that B-Myb deficiency has no effect on the immune signature of the cell when stimulated by 
non-viral agents.  
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Figure 12: B-Myb depletion doesn’t alter cell immune signature 
A: Quantification mRNA analysis of 4-Hydroxy tamoxifen treated Cag-Mybl2fl/fl and 
Cag+Mybl2fl/fl BMDM, stimulated with Poly I:C (50µg/ml), LPS (50ng/ml) and VSV (MOI 
1.0) (n=5-6) B,C: Representative immunoblots of IFN-responsive molecules in OHTAM 
treated Cag-Mybl2fl/fl and Cag+Mybl2fl/fl BMDCs’ stimulated with Poly I:C (50µg/ml) for 7 
hours (B) and LPS (50ng/ml) for 10 and 60 min (C) (n= 3). 
 
3.1.5 Adaptive antiviral response is dependent on B-Myb dependent VSV replication. 
The adaptive immune system presents us with the next line of defense in an infection 
scenario. Successful activation of the adaptive immune system depends on the efficient 
presentation of the antigen by APCs, which further require viral replication in APCs specially 
in CD169+ macrophages15. Activation of adaptive immunity can be measured by various 
methods, one such method is measurement of IFNg producing CD8+ and CD4+ T-cells. We 
infected control and B-Myb deficient mice with 2x106 PFU VSV and harvested the spleen at 
day 8 post infection. The spleen cells were then stimulated with VSV- peptide p52 (CD8+ T-
cell specific) and p8 (CD4+ T-cell specific) for 1 hour and then processed for intracellular 
IFNg staining.  B-Myb deficiency led to significantly impaired viral responses in both CD8+ 
(Fig. 13A) and CD4+ T-cells. (Fig. 13B).  As in VSV infection, the B-cell response plays an 
B C 
Piyush	Sharma	 51	
	
important role in the clearance of the virus via production of neutralizing antibodies. We 
checked the B-cell response in control and B-Myb-deficient mice. We infected control and B-
Myb deficient mice with 2x106 PFU VSV and then took serum samples at the mentioned 
days for neutralizing antibody analysis. Upon analysis, we found significantly reduced VSV-
specific total neutralizing antibodies in B-Myb deficient mice as compared to control mice 
(Fig. 13C). To further verify if the antibody production was completely virus dependent and 
not B-Myb dependent, we made use of UV-inactivated VSV virus. We infected both control 
and B-Myb deficient mice with the higher PFU of UV-inactivated VSV as of active VSV 
virus i.e. 2x108 PFU and then measured the total neutralization antibodies from serum 
samples. We found no significant difference in the production of total neutralizing antibodies 
in B-Myb deficient mice (Fig. 13C, right panel) which confirmed that B-Myb doesn’t affect 
the B-cell response by itself rather by limiting early virus replication. This is in-line with our 
observed phenotype of reduced early VSV replication in CD169+ macrophages, which in-turn 
presents less antigen thus reducing significantly the adaptive immune response.  
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Figure 13: B-Myb dependent VSV replication is crucial for adaptive immune activation 
A: Original FACS blot and quantification of intracellular IFN-g producing CD8+ T-
cells from spleen of tamoxifen treated Cag-Mybl2fl/fl and Cag+Mybl2fl/fl mice infected i.v. 
with 2x106 PFU VSV, 8 days p.i. (n=6) B: Intracellular IFN-g producing CD4+ T-cells from 
2x106 PFU VSV i.v. infected Cag-Mybl2fl/fl and Cag+Mybl2fl/fl mice, 8 days p.i. (n=6) C: 
VSV-neutralizing total Ig from serum of tamoxifen treated Cag-Mybl2fl/fl and Cag+Mybl2fl/fl 
mice  infected with either 2x106 PFU VSV or 2x108 PFU UV-inactivated VSV (n=5-6). 
 
3.1.6 Antiviral adaptive response is independent of B-Myb. 
As mentioned earlier, B-Myb is an important transcription factor which regulates 
cellular proliferation and differentiation. We wondered whether B-Myb deficiency has an 
effect on adaptive cell expansion upon antigen presentation and thus on adaptive immune 
response. To answer this, we made use of two transgenic mice with VSV-specific CD4+ T-
cell and B-cells (Fig. 14A). As these mice are not transgenic for B-Myb, thus expression of 
B-Myb in these mice remains as that of control. Tg7 Thy1.1 mouse have a VSV-specific 
CD4+ T-cell antigen receptor and can be differentiated with the expression of CD90.1 instead 
of CD90.2 on lymphocytes. Due to presence of the transgene, CD4+ T-cells expands rapidly 
once presented with VSV-antigen and thus were made use in the present study. We compared 
the expansion of VSV-specific CD4+ T cells in both control and B-Myb deficient mice after 
infection. We transferred splenocytes from Tg7 Thy1.1 into control and B-Myb deficient 
mice and infected with 2x106 PFU VSV 24 hours later. Mice were then sacrificed at day 4 
post-infection and spleen was harvested for FACS analysis. Results showed significantly 
reduced expansion of VSV-specific CD4+ T-cell (Fig. 14B). This implied that the reduced T-
cell effect in B-Myb deficient mice is the result of the abrogated early VSV replication. 
Next, we evaluated the effect of B-Myb on B-cell expansion and thus in-turn antibody 
production. For this we made use of the transgenic mouse model Vi10 x CD45.1 expressing 
VSV-specific B-cell receptor as knock-in, thus this mouse when presented with VSV results 
in rapid expansion of B-cells. For the experiment, we harvested the splenocytes from Vi10 x 
CD45.1 mice and labeled them with CFSE for 10 min in PBS. CFSE is a chemical which, 
when added to cells, binds to the cellular phospholipid bilayer. Thus, the cellular division can 
be tracked as the intensity of CFSE reduces each time a cell divides. We then adoptively 
transferred these splenocytes into control and B-Myb deficient mice and infected with 2x106 
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PFU VSV 24 hours later. Mice were then sacrificed 4 days post-infection and spleen were 
harvested for FACS analysis. Results showed significantly less expansion of VSV-specific B-
cells in B-Myb deficient mice (Fig. 14C). These results suggest that B-cell response to the 
antigen is dependent on virus replication rather on B-Myb. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: Antigen-dependent T and B-cell proliferation is independent of B-Myb 
A: Experimental schematic of Tg7Thy1.1 and Vi10 CD45.1 splenocytes transfer and 
proliferation analysis.  B: Frequency of adoptively transferred VSV-specific CD4+ T-cells in 
tamoxifen treated Cag-Mybl2fl/fl and Cag+Mybl2fl/fl mice, infected with 2x106 PFU VSV i.v. 
analyzed 4 days p.i. (n=6-7) C: Quantification of CFSE labelled CD45.1 VSV-specific B-
cells transferred in tamoxifen treated Cag-Mybl2fl/fl and Cag+Mybl2fl/fl mice, infected with 
2x106 PFU VSV i.v. analyzed 4 days p.i. (n=5) (naïve n=3). 
 
3.1.7 B-Myb dependent early VSV replication is crucial for host survival. 
Early virus replication in splenic APCs is crucial for an effective immune response. 
During the early infection cycle, viruses replicate in spleen APCs which then process these 
pathogens and presents them to adaptive immune system for their activation along with the 
release of pro-inflammatory cytokines. Failure of early virus replication leads to reduced 
immune activation and thus further escape of virus to vital organs.  
In B-Myb deficient mice, we have shown till now that the early virus response is 
abrogated and thus so the adaptive immune response as well. With the inability of VSV to 
replicate in the spleen, the virus then tries to escape to other organs for its survival and 
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replication. We checked in our experimental model, if the VSV escapes to other organs and 
replicates. As the tamoxifen induced knockdown is not a total body knockdown and our 
optimized dose effect spleen and bone marrow the most, the virus has multiple other tissues 
to facilitate its replication. Thus, we infected control and B-Myb deficient mice with 2x106 
PFU VSV and sacrificed the mice 8 days post infection. Brain and spinal cord were harvested 
for viral titer analysis via plaque forming assay. Results revealed significantly high viral titers 
in both brain and spinal cord in B-Myb deficient mice than control mice (Fig. 15A). This 
indicates the escape of virus to the CNS of the B-Myb deficient mice due to its inability to 
replicate in spleen. As mentioned earlier that VSV is a cytolytic virus and thus leads to cell 
lysis upon infection, we checked for the survival of our mice models. We infected control and 
B-Myb deficient mice with non-lethal VSV PFU of 2x106. More than 80% of B-Myb 
deficient mice developed paralysis in both legs by day 8-10 and were sacrificed. whereas all 
the control mice were able to control VSV and didn’t develop paralysis (Fig. 15B). 
Next, we wondered if conditional B-Myb knockdown has an effect on the survival of 
the host. Therefore, we treated control and B-Myb transgenic mice with the optimized dose 
of tamoxifen and were kept under analysis for up to 30 days. Both the control and B-Myb 
transgenic mice showed no signs of stress or pain and survived till 30 days (Fig. 15B). Taken 
together, we showed that B-Myb is crucial for early virus replication and thus in-turn 
enabling the virus control and effective immune priming and survival of the host. 
 
 
 
 
 
 
 
 
Figure 15: B-Myb dependent early VSV replication is crucial for host survival. 
A: Infective VSV titers from brain and spinal cord from tamoxifen treates Cag-
Mybl2fl/fl and Cag+Mybl2fl/fl mice, infected with 2x106 PFU VSV i.v. analyzed 8 days p.i. 
(n=4) B: Survival of tamoxifen treated Cag-Mybl2fl/fl and Cag+Mybl2fl/fl mice, either non-
infected or infected with 2x106 PFU VSV i.v. (n=5-6). 
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3.1.8 Global requirement of B-Myb by viruses for replication. 
We have shown that VSV replication is dependent on B-Myb which is important for 
the immune activation and thus in-turn virus control. As B-Myb is a ubiquitously expressed 
protein which is conserved evolutionary and is a major transcription factor, we wondered if 
the observed phenomenon of B-Myb dependent viral replication is globally recapitulated in 
different RNA and DNA viral models. To check this, we made use of two more murine virus 
models LCMV and MCMV.  
LCMV is a cytopathic RNA virus. It also replicates in CD169+macrophages during its 
initial replication and its control is majorly T-cell dependent. To check if B-Myb is also 
crucial for early LCMV replication, we infected control and B-Myb deficient mice with 
2x106 PFU LCMV intravenously. Mice were then sacrificed 24 hours later and spleen was 
harvested for immunohistochemistry and viral titer analysis. Upon staining of the spleen 
tissue to check the viral nucleoprotein NP, we found significantly reduced replication of 
LCMV in CD169+ macrophages in B-Myb deficient mice as compared to control mice (Fig. 
16A) which is also reflected by reduced infective viral titers as analyzed by plaque forming 
assay (Fig. 16B). Reduced early LCMV replication in spleen leads to ineffective priming of 
T-cells. To check this, we infected control and B-Myb deficient mice with 2x104 PFU LCMV 
and sacrificed at day 8 post-infection. Both liver and spleen were harvested and intracellular 
cytokine staining was performed to check for the activated CD8+ T-cells stimulated with 
gp33 peptide. We found that B-Myb deficient mice showed reduced IFNg producing CD8+ T-
cells than compared to control (Fig. 16C). Thus, reduced LCMV replication led to ineffective 
priming of T-cells in B-Myb deficient mice. 
MCMV is a DNA virus and also cytopathic. Infection and successful pathogenesis of 
MCMV is not completely dependent on CD169+ macrophages. Rather reports have shown its 
replication in marginal zone macrophages and eventually in red pulp during the early stages 
of replication147. To check whether MCMV replication is also dependent on the expression of 
B-Myb, we infected control and B-Myb deficient mice with 5x105 PFU of MCMV-GFP and 
sacrificed 24 hours later. Spleen was harvested for immunohistochemical analysis. Upon 
staining with GFP for MCMV-GFP, we found significantly reduced MCMV infected cells in 
B-Myb deficient mice (Fig. 16D). Clearance of MCMV is majorly T-cell dependent148, 149. To 
study this, we infected control and B-Myb deficient mice with 1x105 PFU MCMV-GFP. The 
mice were sacrificed 8 days post-infection and liver and spleen was isolated. Organs were 
then crushed in medium and cells were subjected to intracellular cytokine staining after 
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stimulation with H-9-I peptide for CD8+ T-cells. Results showed significantly less IFNg 
producing CD8+ T-cells in B-Myb deficient mice (Fig. 16E).  
Next, we wondered whether the dependence on B-Myb for replication also applies to 
human viruses. We made use of HSV-1 and HIV luciferase reporter particles. Here we 
transfected MCF-7 cells with control scrambled or B-Myb specific siRNA and infected with 
HSV or HIV (MOI 1.0) particles. Viral titers were analyzed 24 hrs p.i. (Fig. 16F) 
Compiling all the results in these experiments, we show that B-Myb is a major host 
factor important for the replication of a broad range of viruses. The dependence on B-Myb is 
a crucial viral replication step which further leads to the activation of adaptive immune 
system. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 16: B-Myb has broad pro-viral capacity 
A,B: Immunofluorescence of LCMV-NP(A) along with infective LCMV titers (B)	from 
spleen of tamoxifen treated Cag-Mybl2fl/fl and Cag+Mybl2fl/fl mice, infected with 2x106 PFU 
Figure : B-Myb has broad pro-viral capacity 
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Figure 16: B-Myb has broad pro-viral capacity 
A,B: Immunofluorescence of LCMV-NP(A) along with infective LCMV titers (B)	
from spleen of tamoxifen treated Cag-Mybl2fl/fl and Cag+Mybl2fl/fl mice, infected with 2x106 
PFU LCMV i.v. analyzed 24 hrs p.i. (n=5) C: Intracellular IFN-g staining of CD8+ T-cells 
from liver and spleen of tamoxifen treated Cag-Mybl2fl/fl and Cag+Mybl2fl/fl mice, infected 
with 2x106 PFU VSV i.v, analyzed 8 days p.i. (n=5-6). D: Immunohistochemical staining of 
MCMV-GFP in spleen of tamoxifen treated Cag-Mybl2fl/fl and Cag+Mybl2fl/fl mice, infected 
with 5x105 PFU MCMV i.v, analyzed 24 hrs p.i. (n=5) E: Intracellular IFN-g staining of 
CD8+ T-cells from liver and spleen of tamoxifen treated Cag-Mybl2fl/fl and Cag+Mybl2fl/fl 
mice, infected with 1x105 PFU MCMV i.v, analyzed 8 days p.i. (n=4). F: HSV plaque assay 
and HIV luciferase assay on control and B-Myb siRNA treated MCF7 cells (day -1), infected 
with MOI 1.0 HSV or HIV luciferase particles (day 0), analyzed 24 hrs p.i. (n=3). 
 
3.1.9 B-Myb depletion leads to down-regulation of multiple gene expression upon VSV 
infection. 
As discussed before, B-Myb is an important transcription factor. Deletion of B-Myb 
leads to embryonic lethality due to abrogated expression of multiple genes required for 
cellular differentiation and proliferation. Here we wondered the effect on B-Myb on the 
cellular gene signature after VSV infection. We infected control and B-Myb depleted mice 
with 2x108 PFU VSV and harvested the spleen 8 hours later. mRNA was isolated from the 
whole spleen and was subjected to microarray analysis. We performed a transcriptome 
profiling with the whole spleen in both control and B-Myb depleted mice and also compared 
to naïve. In the Fig. 17A, we can see that the expression of the majority of genes is down-
regulated with the depletion of B-Myb. 
 
3.1.10 B-Myb dependent host-factors are required for successful viral replication. 
Host factors are the cellular factors which are required by the virus for its successful 
replication. These host factors vary in molecular functions ranging from endocytosis to 
transcription and translation all the way towards the budding of the virions150. Being a part of 
the host cellular machinery, these factors are mostly evolutionary conserved and 
transcriptionally regulated. As B-Myb regulates and modulates a variety of cellular pathways, 
we investigated the effect of B-Myb on the host-factors required for virus replication.  
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We identified the genes which were regulated by B-Myb as transcription factor, we 
analyzed the probable binding sites of B-Myb using MatInspector suite of Genomatix 
software151. We ran the identification of probable genes with the default parameters of the 
MatInspector and obtained the probable gene hits. Then the gene list was sorted with a matrix 
similarity cutoff value of >0.8. The sorted gene list was then enriched for their biological 
processes using GO enrichment analysis based on PANTHER classification system152. The 
results revealed B-Myb regulation of transcriptional activity of RNA polymerase in a very 
significant manner along with DNA transcription and RNA metabolic activity (Fig. 17B). 
These results come in the agreement of our observed results of reduced viral RNA and thus 
impaired viral replication.  
Here, we showed that B-Myb is regulating variety of genes including that of 
transcription and translation related ones. So, we wondered the direct effect of B-Myb on the 
known host factors for VSV replication. Many reports have identified the host factors which 
are crucial for VSV replication153, 154. Therefore, we analyzed selective host factors which 
plays role in transcription and translation, viral uncoating, vesicular transport during viral 
entry and processing, etc. We generated bone marrow derived macrophages (BMDM) from 
control and B-Myb floxed mice and treated them with 7.5µM OHTAM for 48 hours. BMDM 
were then harvested for mRNA expression analysis for various host factors. We found 
significant down-regulation in the expression of genes associated with transcriptional and 
translational activities (Fig. 17C). Next, we harvested spleen from control and B-Myb 
deficient mice and RNA was isolated for expression analysis of the host factors. The results 
obtained were similar to our in-vitro results and showed significantly reduced expression of 
multiple host factors required for RNA processing and translation along with vesicular 
transport and uncoating (Fig. 17D). We found that B-Myb is not only crucial for a regulated 
successful cell proliferation but also regulates multiple factors that aids in viral replication, 
ensuring successful viral replication.  
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Figure 17: B-Myb facilitates expression of pro-viral host factors 
A: Volcano plot illustrating differential expressed genes analyzed from microarray of spleen 
of tamoxifen treated Cag-Mybl2fl/fl and Cag+Mybl2fl/fl mice, infected with 2x108 PFU VSV 
i.v. analyzed 8 hrs p.i. (n=3) B: Major pathways regulated by B-Myb analyzed by gene 
enrichment of B-Myb binding genes extracted from MatInspector Suite. C,D: Quantitative 
mRNA analysis of essential host factors from OHTAM treated BMDMs (C) and tamoxifen 
treated spleen (D) of Cag-Mybl2fl/fl and Cag+Mybl2fl/fl mice E: Intracellular IFN-g staining of 
CD8+ T-cells from liver and spleen of tamoxifen treated Cag-Mybl2fl/fl and Cag+Mybl2fl/fl 
mice, infected with 1x105 PFU MCMV i.v, analyzed 8 days p.i. (n=4). 
 
RESULT 2: B-Myb dependent LCMV replication suppress tumor growth 
	
3.2.1B-Myb facilitates replication of LCMV in tumors. 
We have shown that B-Myb is important for virus replication both in-vitro and in-
vivo. It is well-established that many tumors express high levels of B-Myb, which increases 
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their oncogenic potential90. Mutation of B-Myb alleles results in enhanced B-Myb expression 
in tumors and further it also acts in up-regulation of another oncogene retinoblastoma. It has 
been shown that viruses preferentially replicate in tumors155, 156, due to multiple factors which 
are higher in tumor such as availability of metabolic resources, cellular transcriptional 
machinery and enhanced expression of viral binding factors on cell surface. 
We compared the expression of host-factors in engrafted tumor cells as well as in a 
spontaneous HCC model and their primary counterparts via RT-PCR and 
immunohistochemistry. The experiment revealed significantly higher expression levels of 
both B-Myb (Fig.18A) and host-factors (Fig. A2) in RT-PCR as well as much higher 
presence of phosphorylated B-Myb in tumor cells of subcutaneously established tumors (Fig. 
18B). Next, we wondered about the viral replication capacity in primary untransformed cells 
versus tumor cells. We cultured various different tumor cells along with their primary 
counterparts and infected them with MOI 1.0 LCMV for 48 hours to perform 
immunocytochemistry of LCMV-NP. Analogously, cells were grown in 24-well plates and 
infected them with LCMV MOI 1.0 to collect supernatant for infective viral titer analysis for 
three consecutive days. Immunocytochemistry showed clear presence of LCMV-infection 
of most tumor cells when compared to primary cells (Fig. 18C). Confirmingly, plaque 
forming assay revealed significantly higher replication of LCMV in tumor cells than their 
primary non-transformed counterparts (Fig. 18D). Here we showed that B-Myb is highly 
expressed in tumor cells which is one of the factors required for their strong proliferation. It 
has been long established that virus preferentially replicates in tumor cells. Our data 
reveal, that indeed knockdown of B-Myb in a tumor cell disrupts the virus replication and 
thus B-Myb could be considered as one of the major factor regulating virus replication 
in tumor cells.  This is in line with our data showing rapid infection and enhanced 
replication of LCMV in cancer cells when compared to their primary untransformed cells 
types.  A B 
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Figure 18: B-Myb-dependent LCMV replication in tumors 
A,B: Quantification mRNA expression analysis of B-Myb (A) and immunocytochemistry of 
phospho-B-Myb (B) in mentioned tumors compared to respective healthy tissue (n=9-10) 
(scale-200µm). C: Immunofluorescence of LCMV-NP of human tumor cells and tissue 
matched un-transformed cells, infected with LCMV MOI 1.0, analyzed 48 hrs p.i. (n=3). D: 
Infective LCMV titers from human normal untransformed cell and respective tumor cells, 
infected with LCMV MOI 1.0 (n=6).  
3.2.2 Preferential replication of LCMV leads to tumor regression. 
Viruses have long been proposed as therapeutics for tumor treatment as they can 
selectively infect cancer cells causing damage to cancerous tissues with limited collateral 
damage to normal host tissue. Various ways have been employed to use viruses as tumor 
therapy such as modified and attenuated or as adjuvants. Viruses have been sought as a major 
therapeutic agent for tumor therapies, especially oncolytic viruses157-159. The specific 
mechanism of virotherapy have long been considered to be directly oncolytic. In cancer 
therapies with oncolytic viruses, this is considered to be a limited collateral effect. 
Arenaviruses on the other hand have been explored less frequently in terms of tumor 
therapy160. Thus, we wondered the replication of LCMV in tumor and its effect on tumor 
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growth. For this we injected a oropharyngeal tumor cells MOPC to establish subcutaneous 
tumors in mice. Once the tumor reached a specific size, we injected 2x104 PFU LCMV 
peritumorally along with the medium as control in the other mice. Following the course of 
the tumor growth, we saw complete regression of tumor in LCMV-treated mice than 
compared to the control (Fig. 19A) leading to longer survival and being relapse-free during 
the observational time (Fig. 19A).  Upon checking if the time of LCMV infection has any 
effect on the tumor regression using more advanced tumor, we found significant reduction of 
tumor sizes in LCMV treated mice (Fig. 19B). In line with decreased tumor burden, again 
LCMV-treated mice showed better survival than MOCK-treated mice. Next, we checked 
whether LCMV is can be used systemically to effect distant tumors. To mimic metastatic 
stage, we used tumors grafted in abdominal flank and shoulder and treated the mice with 
2x104 PFU LCMV intravenously. We found that the systemic treatment of LCMV results in 
tumor suppression in both shoulder and flank (Fig. 19C). As viruses display preferential 
proliferation and anti-tumoral activity after local and systemic delivery, we expanded our 
observations on different engrafted and spontaneous tumor models. We cultured MC38 colon 
carcinoma cells and B16 lung carcinoma and engrafted them into the flanks of WT mice. 
Once the tumors were established, we treated one group with LCMV peritumorally and the 
other with medium. With the course of tumor growth, we observed similar effect of LCMV 
as both MC38 (Fig. 19D) and B16 (Fig. 19E) tumor growth was significantly inhibited in the 
LCMV treated mice.  
As engrafted models of cancer still don’t represent the normal scenario of 
disseminated malignant disease, we made use of spontaneous mouse tumor models. These are 
the transgenic mice which develop endogenous tumors during the duration of their life cycle. 
MT/ret melanoma model develop visual endogenous cutaneous malignant melanoma. We 
injected MT/ret mice with LCMV i.v.  once the tumors were palpable.  On day 15, mice were 
sacrificed and tumor nodules in the skin were counted. We found that the LCMV-treated 
MT/ret mice had reduced macroscopically detectable tumor nodules compared to controls 
(Fig. 19F). Next, we used LoxP-Tag mice, which develop endogenous hepatocellular 
carcinoma with age. In this experiment, we used 9-10 months old mice with palpable liver 
tumors and infected them with 2x106 PFU LCMV i.v. The mice were then observed and 
sacrificed 6 and 20 days post-infection. Liver was taken out and macroscopic nodules were 
counted. We found significant early reduction in the tumor nodules in the LCMV treated 
mice (Fig. 19H) at day 6 which can be seen by the overall architecture of the liver (Fig. 19G).  
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The reduction in the tumor nodules continued to decrease significantly as seen by the analysis 
of the liver at day 20 (Fig. 19H). 
Figure 19: LCMV treatment leads to tumor regression and host survival 
A: Tumor size and survival of MOPC tumor bearing mice (day -3) treated with 2x104 PFU 
LCMV peritumorally (n=10). (B) tumor size and survival of advanced MOPC-tumor bearing 
mice (day-10), treated with 2x104 PFU LCMV peritumorally (n=10). C: Tumor size of 
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shoulder and flank of MOPC-tumor bearing mice on shoulder and abdominal flank, injected 
with 2x106 PFU LCMV intravenously (n=6). D,E: Tumor size of WT mice bearing MC38 
(D) and B16F10 (E) tumor (day-3) treated with 2x104 PFU LCMV peritumorally. (n=6-7). F:
Number of melanomas in MT/ret (day 15), treated with 2x104 PFU LCMV systemically
(n=3-4) G,H: Representative picture (day 6 p.i., n=3) and macroscopic nodule quantification ( 
day 6 n=3, day 20 n=6) of/in livers of LoxP-Tag mice bearing spontaneous HCC, treated with 
2x106 PFU LCMV systemically (scale- 0.5cm)  
3.2.3 LCMV treatment leads to the immune infiltration in tumors. 
Various reports have shown that the major cell types to infiltrate the tumor are T-cells 
specifically CD8+ T-cells. It has been recognized that induction of inflammatory response is 
crucial to virus mediated tumor regression. Presence of immune infiltrates determines the 
progression of the tumor as well as the survival of the host. Studies have correlated the 
immune infiltration with the prognosis of the tumors161-163. 
LCMV infection leads to activation of both innate and adaptive immune system. This results 
in the infiltration of the immune cells to the site of infection. We therefore checked for the 
immune cells in our model of LCMV induced tumor regression. We engrafted 5x105 cells 
subcutaneously on the right flank of the mice and injected 2x104 PFU LCMV peritumorally 
once the tumors are palpable. Tumors were then harvested 10 days post infection and were 
subjected to immunofluorescence analysis for the presence of various immune infiltrates. 
Results displayed high infiltration of CD8+ T-cells along with CD4+ T-cells in LCMV-
infected tumors. Interestingly, high amount of Ly6C+ monocytes were also found in LCMV-
infected tumors. However, we didn’t observe any presence of B-cells (Fig. 20A). We also 
analyzed draining lymph nodes for the presence of immune cells and found strong infiltration 
of inflammatory Ly6C+ monocytes in LCMV-treated mice (Fig. 20B). These results 
cumulatively show the strong activation and accumulation of inflammatory monocytes as 
well as T-cells during the LCMV-mediated tumor regression.  
A 
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Figure 20: LCMV treatment leads to immune infiltration 
A: Immunohistochemistry analysis of MOPC tumors of C57BL6/J (day -10) treated with 
2x104 PFU LCMV peritumorally, analyzed 10 days p.i. (n=3) (scale 200µm). B: 
Immunohistochemistry of draining lymph nodes from MOPC tumor bearing C57BL6/J mice 
treated with 2x104 PFU LCMV peritumorally (n=3) (scale 200µm). 
3.2.4 LCMV-induced Tumor regression is dependent on immune infiltration. 
As shown by the above results, LCMV treatment leads to immune infiltration in the 
tumors.  Thus, we wondered whether the tumor regression is due to the LCMV-induced 
immune infiltration or solely depends on LCMV replication. To answer this query, we made 
use of Map3K14aly/aly mice which lack both humoral and cell-mediated immune response and 
lymph nodes due to the defects in Nf-kB signaling133. We engrafted WT and Map3K14aly/aly
mice with MOPC cells and treated one group with 2x104 PFU LCMV peritumorally. Tumor 
growth was measured with the course of time. Results showed that LCMV-treated tumor 
bearing Map3K14aly/aly mice were unable to control the tumor whereas LCMV-treated WT 
mice showed efficient tumor regression (Fig. 21A), indicating that LCMV-mediated tumor 
regression depended on the activation of immune defenses. 
3.2.5 Presence of IFN-I leads to LCMV-induced tumor regression. 
Our previous results have established the presence of monocytes and adaptive 
immune infiltrates in the tumor when treated with LCMV along with the importance of innate 
immune response in tumor regression. Monocytes have been long known as the strong 
inducer and mediator of IFN-I164, 165 upon innate sensing and vice versa. Monocytes are 
found in blood and are associated with tumor as myeloid-derived suppressor cells (MDSC). 
MDSC in mice are basically composed for Ly6Chi monocytes and Ly6Ghi granulocytes. 
Among these, Ly6Chi cells display high plasticity and contribute to inflammatory monocytic 
MDSC population associated with tumor suppression166, 167. 
B 
Piyush	Sharma	 66	
To investigate the role of IFN-I in LCMV-mediated tumor regression, we used ifnar-/- 
mice. IFNAR mice lack IFNAR1 and IFNAR2 interferon receptors and thus IFN signaling is 
abolished. We injected 5x105 MOPC cells subcutaneously in WT and ifnar-/- mice and either 
left the mice un-treated or treated them with 2x104 PFU LCMV injected peritumorally. 
Tumors were measured during the course of time. Analysis revealed no significant difference 
in tumor bearing ifnar-/- mice when compared to LCMV treated tumor bearing WT mice (Fig. 
21B), indicating that IFNAR expression on host cells was not crucial for LCMV- cancer 
therapy. To explore further the involvement of IFN in the LCMV-mediated tumor response, 
we made use of Irf3-/-x Irf7-/- double knockout mice. These mice lack Irf3 and Irf7 genes 
which are the regulatory factors for the transcription of Interferon. We engrafted WT and 
Irf3-/-x Irf7-/- mice with MOPC tumors and injected 2x104 PFU LCMV peritumorally. The 
tumor size was analyzed within the course of tumor growth in both groups. The anti-tumoral 
effect LCMV was blunted in tumor-bearing Irf3-/-x Irf7-/- mice treated compared to WT 
control mice (Fig. 21C). Taken together, the results displayed the crucial role of IFN-I in 
LCMV-treatment of tumors, acting rather directly on tumor cells than on host cells. 
 
Figure 21: Anti-tumor LCMV effect is dependent on immune infiltration and host IFN. 
A: Tumor measurement of MOPC-tumor bearing WT or Map3K14aly/aly (day -3) treated with 
(n=8 WT; n=6 Map3K14aly/aly) or without (n=7 WT; n=6 Map3K14aly/aly) 2x104 PFU LCMV 
A B 
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peritumorally. B: Tumor measurement of MOPC-tumor bearing WT and Ifnar-/- mice either 
untreated (left) or treated (right) with 2x104 PFU LCMV peritumorally (n=6-7). 
3.2.6 Monocytic IFN production leads to tumor regression with LCMV treatment. 
As IFN-I is produced by many cell types, we wondered if MDSC monocytes have a 
role in the current model. Thus, we made use of IFN-b reporter mice established as 
IFNbmob/mob mice168, these mice have a GFP reporter tagged IFN-b gene and thus expression 
of the same can be detected. We established tumors in WT and IFNbmob/mob mice and infected 
them with 2x104 PFU LCMV peritumorally, once the tumors were palpable. Draining lymph 
nodes were harvested on 2 days post-infection and analyzed for GFP signals via FACS. 
Results showed that the IFN-b was produced by Ly6C+ monocytes in LCMV infected tumor 
bearing mice with the molecular signature as mPDCAhi, CD11cmed and B220med which 
suggests their differentiation into interferon producing cells (Fig. 22A). To strengthen further 
our results of IFN dependence in LCMV mediated tumor reduction, we analyzed various 
IFN-I associated genes expression from draining lymph nodes of LCMV-treated tumor 
bearing mice, sacrificed on 3 days post 2x104 PFU LCMV infection along with the analysis 
of blood serum IFN-a levels. We found significantly high expression of IFN related genes 
along with high serum IFN-a levels in LCMV-treated tumor-bearing mice as compared to 
tumor-bearing WT mice (Fig. 22B). These results prove conclusively the high expression of 
type-I IFN in our LCMV-tumor model. To further investigate the role of monocytes in our 
observed tumor regression, we used different antibodies for depletion of various monocytic 
populations. For this experiment, we used two different antibodies; a-Gr-1 (clone RB6-8C5) 
which binds to both Ly6G+ and Ly6C+ cells169, 170 and a-Ly6G (clone 1A8) antibody which 
specifically binds to Ly6G+ cells. Mice were treated with three consecutive treatments of 
200µg of a-Gr-1 antibody at day -2, 2 and then 7 of 5x105 MOPC cells injection. Second 
group of mice were treated with 500µg of a-Ly6G antibody at day -2, 2 and 7 of MOPC cell 
injection. In both experiments isotype-treated mice were used as control. All the groups were 
then injected with either control or 2x104 PFU LCMV peritumorally. The mice were 
observed for their tumor growth and tumor size was analyzed. In the group treated with a-Gr-
1 antibody resulting in depletion of both Ly6G+ and Ly6C+ cells, LCMV showed no effect on 
tumor growth as compared to isotype treated mice (Fig. 22C). Whereas mice treated with a-
Ly6G antibody showed tumor reduction with LCMV treatment same as that of isotype treated 
WT control (Fig. 22D). To investigate whether the recruitment of monocytes is necessary for 
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the IFN mediated tumor regression, we employed Ccr2-/- mice. Ccr2 (chemokine receptor 2) 
is a major receptor for monocyte chemoattractant proteins (MCPs)171, which is one of the 
potent chemoattractant for multiple cell types including monocytes172, immature dendritic 
cells173, memory T-cells174 and NK cells175. Thus Ccr2-/- mouse presents impaired 
recruitment of monocytes and reduced monocyte number. We injected WT and Ccr2-/- mice 
with 5x105 MOPC cells subcutaneously and once the tumors were palpable, 2x104 PFU 
LCMV was injected peritumorally. The tumor growth was then measured for 28 days. We 
observed significantly impaired anti-tumoral effect of LCMV in Ccr2-/- mice as compared to 
WT mice (Fig. 22E). Taken together we show that Ly6C+ monocytes play an important role 
in the control of tumors in LCMV treated mice via the induction and release of type-I IFN.  
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Figure 22: Monocytic Ly6C+ IFN-I drives LCMV mediated tumor regression 
A: Representative FACS blots from draining lymph nodes of MOPC-tumor bearing WT and 
IFNbmob/mob mice treated with 2x104 PFU LCMV peritumorally, analyzed day 2 p.i. (n=4); 
Grey area-isotype control. B: qRT-PCR analysis from draining lymph nodes (left; n=3) and 
serum IFN-a levels (right; n=4) from MOPC-tumor bearing mice either treated or untreated 
with 2x104 PFU LCMV peritumorally, analyzed 3 days p.i. C: Tumor measurement of 
MOPC-tumor bearing WT mice injected with or without a-Ly6G+C antibody (200µg), 
treated with (n=6) or without (n=6-7) 2x104 PFU LCMV peritumorally. D: Tumor 
measurement of WT mice injected with or without a-Gr-1(Clone1A-D)(500µg), treated 
without (left0 or with (right) 2x104 PFU LCMV peritumorally (n=3-4). E: Tumor 
measurement of MOPC-tumor bearing WT and Ccr2-/- mice, treated without (n=6; left) or 
with (n=9; right) 2x104 PFU LCMV peritumorally. 
We investigated the role of adaptive immune cells and also NK-cells in the LCMV dependent 
tumor suppression. As the adaptive immune system plays a crucial role in the immunity 
against cancer, we were wondering if these cells play a crucial role in our observed 
suppression of tumors. We use Tcrb-/-, Jh-/- knockout mice to study the role of T cells and B 
cells. Tcrb-/- mice lack the TCR-a/b chains of their receptors. This leads to the major 
reduction in total number of cells in thymus which can be seen by reduction of CD4+CD8+
cells by upto 90% than that of WT. The T-cells differentiation and development is blocked at 
an early stage. Jh-/- mice harbor deletion of endogenous J segments of Ig heavy chain locus. 
This leads to the severely impaired development of B-cell lineage resulting in almost 
negligible presence of mature B-lymphocytes and complete absence of IgM and IgG. Here, 
we injected MOPC cells subcutaneously into both Tcrb-/- and Jh-/- along with WT as control 
and once tumors were palpable, medium or 2x104 PFU LCMV was injected peritumorally. 
The tumors were monitored for their growth. We found no significant difference in tumor 
growth in Tcrb-/- (Fig. 23A) and Jh-/- (Fig. 23B) mice when compared to their respective 
controls. Next, we analyzed role of NK-cells in LCMV-dependent tumor suppression. For 
this we used a-NK1.1 depletion antibody which selectively binds and depletes NK cells. We 
injected 400µl a-NK1.1 and control antibody at day -3 and -1 in WT mice leading to 
complete depletion of NK-cells (Fig. 23C) and injected with 5x105 MOPC cells 
subcutaneously. The mice were either treated with 2x104 PFU LCMV or left un-treated. 
Tumor growth was observed for the duration of experiment. Results showed no significant 
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difference in the reduction of tumor between WT and NK-cell depleted mice with LCMV 
treatment (Fig. 23D). Together here we couldn’t find any relevance of T, B or NK-cells in 
arenavirus mediated tumor suppression.  
Figure 23: Monocytic Ly6C+ IFN-I drives LCMV mediated tumor regression 
A: Tumor measurement of MOPC-tumor bearing WT and Tcrab-/- mice (day -3) treated with 
(left) or without (right) 2x104 PFU LCMV peritumorally on day 0 (n=5)  B: Tumor 
measurement of MOPC-tumor bearing WT and Jh-/- mice (day -3) treated with (left) or 
without (right) 2x104 PFU LCMV peritumorally on day 0 (n=5)   C,D: Representative FACS 
dot plot from peripheral blood (C) and Tumor measurement (D) of MOPC-tumor bearing WT 
mice injected with or without a-NK1.1 antibody, treated with or without 2x104 PFU LCMV 
peritumorally (n=4).  
3.2.7 Role of CD8+ T-cells in anti-tumor arenavirus virotherapy. 
T cells play a central role in the design of an anti-tumor therapy176. Due to their ability to 
recognize antigen, infiltrate and to effectively remove the target cells, these are one of the 
preferred cells that are taken into consideration for the therapy. Specifically, CD8+ T-cells are 
of crucial interest in virotherapy. They aid in the removal of virus from the host infected 
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tissue which including tumor tissue but virus treatment also leads to effective tumor-specific 
CD8+ T cells leading to efficient control of tumor growth. As we have shown in the previous 
results (Fig. 20A), LCMV treatment led to significantly increased CD8+ T-cell infiltration, 
and we further examined the presence of virus specific CD8+ T-cell in WT mice infected with 
2x104 PFU LCMV and MOPC-tumor bearing WT mice infected with same PFU of LCMV. 
Upon analysis, we found that indeed virus-specific CD8+ T-cell were induced in both the 
groups but no difference in their numbers were observed (Fig. 24A). T-cell memory plays a 
crucial role in viral infections as to initiate an effective response on the re-encounter of the 
antigen. Same T-cell memory might be able to play a negative role in the arenavirus 
dependent tumor therapies. To explore this hypothesis, we infected Jh-/- mice with 200 PFU 
LCMV i.v for 100 days to induce memory T-cell generation. We then injected WT and 
memory Jh-/- mice with 5x105 MOPC subcutaneously and then injected 2x104 PFU LCMV 
i.v. once the tumors reached desired size. Results showed that the memory Jh-/- mice were 
unable to effectively reduce tumor growth as compared to WT mice (Fig. 24B). This 
indicates that the presence of virus-specific CD8+ T-cells have a potentially negative impact 
on arenavirus mediated tumor therapy. Further we wondered the effect of T cells as such in 
the arenavirus mediated tumor suppression. To examine this, we used Rag1-/- mice which 
lack mature T-cells due to the lack of V(D)J recombination gene Rag132. We injected 5x105 
MOPC cells in WT and Rag1-/- mice and were infected with 2x104 PFU LCMV 
intratumorally once the tumor reached advanced size. We observed enhanced tumor 
suppression and longer host survival in LCMV treated Rag1-/- mice than compared to WT 
mice (Fig. 24C). Next, we checked whether the effect of IFN is correlated with T-cell 
activity. We depleted IFN signaling in WT and Rag1-/- mice by blocking IFN receptors using 
a-IFNAR antibody, injected 10 days post MOPC cells injection. Upon LCMV treatment we 
found that the absence of T-cells prolongs the effect of LCMV-mediated tumor regression 
(Fig. 24D).  Together, we show that the presence of virus-specific CD8+ T-cell mounts an 
early antiviral response resulting in the elimination of LCMV and thus impairing the LCMV-
dependent tumor suppression. On the other hand, absence of T-cells leads to the prolonged 
and more efficient tumor suppression with LCMV treatment.  
Further, we went on to analyze the role of LCMV on the anti-tumor activity of tumor-specific 
CD8+ T-cells. For this we made use of OT-1 mice, which harbor transgenic inserts in TCR 
region thus recognizing ovalbumin177.  We transferred 5x106 splenocytes from OT-1 mice 
into WT mice 10 days after the injection of B16-OVA melanoma tumor cells. The mice were 
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infected with 2x104 PFU LCMV and observed for 8 days. Mice were then sacrificed on day 8 
and tumors were isolated and analyzed for different survival markers for tumor-specific T-
cells.  We observed enhanced expression of IL-2Rb (CD122) and IL-7Ra (CD127) on tumor 
-specific CD8+ T-cells with LCMV treatment as compared to controls (Fig. 24E). Expression
of these factors signals the effectiveness and survival of the cytotoxic T-cells. Next, we
investigated the effect of LCMV treatment in the tumor growth and survival of host with and
without tumor-specific CD8+ T-cells. We injected B16-OVA cells and EL4-OVA lymphoma
cells to establish tumors in the mice.  Once the tumors were established, the mice received
5x106 splenocytes from OT-1, transferred i.v. 24 hours later, mice were either left un-treated
or infected with 2x104 PFU LCMV and observed for tumor growth. We observed significant
reduction in tumor growth in presence of tumor-specific CD8+ T-cells along with LCMV
treatment than alone with LCMV treatment. The results correlated with the survival of the
host in both the cases i.e. B16-OVA melanoma tumors (Fig. 24F) as well as in EL4-OVA
lymphoma tumors (Fig. 24G) Compiling all the results, we found out that LCMV dependent
tumor suppression is enhanced effectively in the presence of tumor-specific CD8+ T-cells.
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Figure 24: Tumor-specific CD8+ cells enhances LCMV mediated tumor suppression 
A: LCMV-specific CD8+ T-cells of MOPC-tumor bearing WT or control mice treated with 
2x104 PFU LCMV (n=3). B: Tumor measurement of MOPC-tumor bearing WT and memory 
Jh-/- mice treated with 2x104 PFU LCMV intravenously on day 0 (n=5). C: Tumor 
measurement and survival (extreme right) of MOPC-tumor bearing WT and Rag1-/- mice 
(day -10), treated with (middle) or without (extreme left) 2x104 PFU LCMV intratumorally 
on Day 0 (n=5). D: Tumor measurement and survival of MOPC-tumor bearing Rag1-/- mice 
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(day -10) injected with a-IFNAR1 antibody or isotype control, treated with 2x104 PFU 
LCMV peritumorally (n=5). E: Expression of PD-1, IL2Rb and IL7Ra on tumor-specific 
CD8+ T cells (OT1) of B16-OVA-tumor bearing WT mice (day -10) transferred with 5x106 
OT1 splenocytes (day -1) and additionally treated with (n=5) or without (n=3) 2x104 PFU 
LCMV i.t. F: Tumor measurement and survival of B16-OVA-tumor bearing WT mice (day -
10) transferred with (n=4) or without (n=5) 5x106 OT-1 splenocytes, treated with or without
2x104 PFU LCMV i.t. G: Tumor measurement and survival of EL4-OVA-tumor bearing WT
mice (day -6) transferred with (n=7) or without (n=4-5) 5x106 OT-1 splenocytes, treated with
or without 2x106 PFU LCMV i.t. 
3.2.8 IFN-I mediated suppression of angiogenesis leads to tumor suppression. 
Angiogenesis refers to the formation of new blood vessels which is crucial for the 
growth and progression of solid tumors. Angiogenesis provides much needed oxygen and 
essential nutrients for the tumor development178. Various factors are secreted by tumor cells 
in order to continuously remodel the tumor micro-environment to sustain regular growth. 
Some of these factors include vascular endothelial growth factor (VEGF) and matrix 
metalloproteinases (MMP). Inhibition of angiogenesis inhibits the tumor development as the 
tumor cells are deprived of nutrients and succumb to apoptosis. IFN-a is known for its 
multiple effects amongst them its anti-angiogenic function117, 179. Studies have shown that 
treatment of IFN-a, have resulted the reduction of tumors in-vivo and in-vitro180, 181. IFN 
treatment results in the reduced secretion of various angiogenic factors such as FGF and 
VEGF. 
As we have shown that the LCMV dependent tumor regression is dependent on the 
infiltration of Ly6C+ monocytes and host IFN-I production, we next wondered the 
mechanism of this anti-tumor activity. We injected 5x105 MOPC cells in to WT mice flank 
and then injected 2x104 PFU LCMV on day 3 of cells injection. Tumors were harvested on 
day 6 post-infection for immunofluorescence analysis and also analyzed for the expression of 
angiogenic regulators via RT-PCR. We found that the expression of almost all the angiogenic 
regulators have been significantly reduced upon LCMV treatment (Fig. 25A). Next, we 
analyzed the expression of CD31 also known as PECAM (platelet endothelial cell adhesion 
molecule-1), which is expressed by the early endothelial cells during angiogenesis. The 
harvested tumors were subjected to CD31 immunostaining. We found significantly reduced 
expression of CD31 in LCMV treated tumors as compared to un-treated tumors (Fig. 25B) 
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Quantification of the same reveals the reduced micro-vessel density (MVD) along with 
increased vessel-to-vessel distance in LCMV treated tumors (Fig. 25B Lower panel). 
Reduction in angiogenesis leads to reduced supplement of the soluble oxygen and essential 
nutrients to the tumor. This further results in the occurrence to increased hypoxic areas and 
apoptosis. We next harvested MOPC-bearing mice infected with 2x104 PFU LCMV, on day 9 
and stained for pimonidazole which is a hypoxia marker182. Results showed increased 
hypoxic areas in the LCMV treated tumors (Fig. 25C) resulting in increased apoptosis 
as observed by cleaved caspase-3 staining (Data not shown). 
Together, we showed that monocytic IFN-I dependent tumor suppression is the result of 
reduced tumor vasculature due to the anti-angiogenic activities of IFN-I. 
Figure 25: LCMV treatment results in IFN-I mediated suppression of angiogenesis 
A: Quantitative mRNA analysis from MOPC-tumor bearing WT or control mice (day -3) 
treated with 2x104 PFU LCMV peritumorally on day 0, analyzed on day 6 (n=3). B: 
Immunofluorescence of CD31 (top) and quantification of microvessel density (MVD) 
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(bottom left) and vessel-vessel distance (bottom right) from MOPC-tumor bearing WT or 
control mice (day -3) treated with 2x104 PFU LCMV peritumorally on day 0, analyzed on 
day 6 (n=3). C,D: Immunohistochemistry (day 6; C) and quantification of hypoxic areas (day 
9; D) from MOPC-tumor bearing WT or control mice (day -3) treated with or without 2x104 
PFU LCMV peritumorally on day 0(n=3). 
3.2.9 LCMV mediated anti-tumor effect is more effective than other oncolytic viruses 
Oncolytic viruses have been into multiple anti-tumor research and also in pre-clinical 
stages. These viruses have been long studied and have found their niche in anti-tumor 
treatment. Oncolytic viruses have been modified and mutated to be better suited as 
therapeutic agents. However, in comparison, arenaviruses have minimal side-effects due to 
their cytopathic nature, restrictive tissue tropism and immune cell mediated control. So, here 
we wondered about the anti-tumor efficacy of the oncolytic viruses as compared to our 
LCMV virus in tumor suppression and host survival. 
For these experiments, we employed two different oncolytic viruses which are either 
currently in clinical or pre-clinical trials. A chimeric VSV variant (VSV-GP)183 is currently 
being developed as an oncolytic therapy for tumors (ww.viraltherapeutics.com), but a similar 
variant is in Phase-I trial of hepatocellular carcinoma (HCC). Another virus is a recombinant 
TK-depleted vaccinia virus with GFP/LacZ integration (TK- VACV-GFP/LacZ, rVACV), 
which is tested as a double mutant in phase-I study of patients with advanced solid tumors184. 
We established MOPC tumors in WT mice by injecting 5x105 cells subcutaneously and 10 
days after injected LCMV, rVSV and rVACV in the indicated dose either intratumorally (Fig. 
26A) or intravenously (Fig. 26B).  We observed limited tumor suppression with rVSV and 
rVACV when compared to LCMV treatment in line with better survival of LCMV treated 
mice. We then also injected 100-fold increased dosage of rVSV and rVACV, but the 
observed anti-tumor effect of these oncolytic viruses was significantly lower than that of with 
LCMV treatment (Fig. 26B). Together here we show that the treatment of tumors with non-
cytolytic arenaviruses have better efficacy than compared to oncolytic viruses, which also 
leads to better host survival.  
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Figure 26: LCMV shows better efficiency and efficacy compared to oncolytic viruses 
A: Tumor measurement and survival of MOPC-tumor bearing WT mice (day -10) treated 
with mentioned PFU of LCMV and oncolytic viruses intratumoraly (n=5). B: Tumor 
measurement and survival of MOPC-tumor bearing WT mice (day -10) treated with 
mentioned PFU of LCMV and oncolytic viruses intravenously (n=5).  
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CHAPTER-4 
DISCUSSION 
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Viruses have been extensively studied and presents an interesting and exciting field to 
explore. They range from being non-pathogenic to pathogenic causing mild to severe damage 
to their host. Multiple disease-causing viruses such as HIV, HBV, Ebola, etc. have posed 
difficult problems through the infection of the human population. Their ability to infect, 
replicate and integrate into the host genome has been explored and exploited in many 
situations. They have been used as therapeutic agents for multiple diseases including cancer 
as modified and inactivated forms. 
Study of viral life cycle has given us the understanding of the complex interactions 
between virus and host. Viruses are the obligate pathogens which are indigent compared to 
their hosts. They carry only minimal required components for their survival and replication 
and thus rely on their host for their replication. Understanding of those host factors provides 
us with the various host cellular contributions towards viral replication. This then in-turn is 
related to the outcome of the immune response towards the virus. They are of continuous 
interest to the research community. With the evolution and emergence of new viruses, it has 
been become quite important to dissect the basic cellular replication of the virus and to 
understand the cellular dependence of viral replication.  
 
The present study deals with the novel functional identification of a transcription 
factor known for its role in cell cycle and cellular proliferation. We have identified B-Myb as 
the major regulator of viral replication which acts via its transcriptional regulation activity of 
multiple host factors. We have also identified that B-Myb assisted viral replication also acts 
as tumor suppression in an IFN dependent fashion, thus establishing LCMV as anti-tumor 
virotherapy.  
 
4.1 Identification of B-Myb role in viral replication 
Multiple factors have been identified till now for viral replication. Viruses also 
modulate and induces expression of many host factors. Due to their rapid replication, viruses 
require high expression of these host-factors. They make this sure by usually restricting cell 
to a certain phase or targeting the master switches of cell cycle regulation. Studies have 
shown that viruses also modulate cell cycle to prioritize their replication185, 186. In other 
words, virus dependence on certain factors might also be related to certain phases of cell 
cycle and thus have developed multiple strategies to manipulate the cell cycle by associating 
with cyclins and cyclin-dependent kinases (CDK)187.  
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One such master cell cycle regulator is B-Myb which regulates the cell cycle through 
G1/S phase towards G2/M phase72. B-Myb is a widely-accepted regulator of cellular 
proliferation by being involved in DREAM complex regulating multiple gene expression 
during cell cycle. B-Myb activity is induced by CyclinA2/CDK2 complex and is 
phosphorylated to be activated81. 
We here discovered that B-Myb phosphorylation is associated with viral replication 
which raised further question of this association. With subsequent experiments, we revealed 
that the phosphorylation of B-Myb occurs during active virus replication (Fig. 6). B-Myb 
phosphorylation is associated with enhancement of its transactivation properties during cell 
cycle via Cyclin A/CDK285. Multiple studies have identified various phosphorylation sites, 
however here we have explored only one phosphorylation site on residue threonine 487 
(T487). In our study, T487 is shown to be phosphorylated during active virus replication. The 
possibility of B-Myb being phosphorylated at other sites owing to its activity during virus 
replication still needs to be explored as does the functional importance of phosphorylation. It 
is unclear whether phosphorylation is merely a surrogate marker for B-Myb expression. With 
this we raised a novel relation of virus replication with B-Myb activity. Next, we wondered 
the importance of B-Myb for viral replication, as it was specifically phosphorylated in virus 
infected cells. We found that not only virus replication triggers B-Myb phosphorylation but 
also transient knockdown of B-Myb abrogates virus replication in-vitro. This presented us 
with the importance of B-Myb for a successful viral replication.  
B-Myb is a ubiquitously expressed protein but expression of B-Myb is high in 
dividing and differentiating cells such as those of the bone marrow. Terminally differentiated 
cells express little or no B-Myb as the requirement of the same for day-to-day cellular 
function is very minimal. Therefore, infection of terminally differentiated cells answers the 
need of B-Myb activation during viral replication. We performed an in-vivo transient 
knockdown of B-Myb in the liver hepatocytes to check whether viral dependent B-Myb 
activation is cell specific. We made use of VSV model in the absence of macrophages, thus 
making VSV migrate to liver and infect hepatocytes.  Interestingly we found that depletion of 
B-Myb from hepatocytes severely impaired VSV replication in liver (Fig. 8). The collective 
results showed that the B-Myb activation is very much dependent on active virus replication 
in a cell-independent manner. This showed that activation of B-Myb is a crucial requirement 
by viruses to establish cellular infection and propagate. However, B-Myb is classically 
activated during cell cycle in a cyclin dependent fashion. The mechanism of viral 
phosphorylation of B-Myb can be a consequence of viral hijacking of cellular transcriptional 
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machinery to manipulate the cell cycle. The relation between viral replication and B-Myb 
phosphorylation still needs to be elucidated.  
 
4.2 Control of viral replication by B-Myb in early virus replication. 
Viruses replicates primarily in specific organs/cells in order to ensure their successful 
propagation. VSV and LCMV as shown from our previous studies15, replicates in CD169+ 
macrophages in spleen during initial infection and early replication. This early replication in 
spleen is enforced by the host and is called enforced virus replication. Replication in CD169+ 
macrophages ensures viral processing and presentation to adaptive immune system for their 
activation and thus abrogation of the same results in impaired immune activation and viral 
control. We studied the role of B-Myb in early virus replication and their respective adaptive 
immune response using VSV as primary model virus and inducible knockout mice model for 
B-Myb. We induced knockdown of B-Myb via tamoxifen administered intraperitoneally. 
Upon infection of B-Myb depleted mice with VSV, we found that the VSV replication is 
abrogated in spleen (Fig. 10). This was in line with the observed results in-vitro and thus 
revealed the importance of B-Myb in viral replication. 
Upon infection, antigen is acquired by APCs for processing. Antigen presentation by APCs 
during a viral infection is the crucial step towards the successful immunity188. Any defect in 
antigen presentation leads to impaired T and B-cell response189, 190. As discussed before, viral 
replication in CD169+ macrophages is important for antigen presentation and adaptive 
immune activation. During a viral infection, T-cells play the role of both cytotoxic T-cell 
portrayed by CD8+ T-cell and helper T-cells portrayed by CD4+ T cells. Both are required for 
an effective and complete eradication of virus as well as the virus-infected cells. B-cells on 
the other hand require their differentiation into antibody secreting plasma cells. They are 
activated by APC and also via Th-1 cells in order to secrete antigen specific antibodies and 
further neutralize the infection. In case of VSV, B-cells plays a major role along with IFN-I 
in the control of the infection191. With our results of reduced VSV replication, we analyzed 
the activation of both T and B-cells in control and B-Myb depleted mice with VSV infection. 
We observed that in B-Myb depleted mice, due to impaired VSV replication CD8+ and CD4+ 
T-cells antiviral response was significantly reduced as seen by IFNg production upon re-
stimulation with their respective viral peptide. Upon analysis of B-cell response via the 
measurement of VSV-neutralizing antibodies, we found significantly reduced response as 
compared to WT (Fig. 13). 
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T and B-cells undergo rapid clonal expansion post antigen recognition. Studies have 
shown that c-Myb is required for differentiation of B-cells192. Thus, requirement of B-Myb in 
clonal expansion leading to the observed defect in adaptive immunity was questioned. We 
showed that VSV-specific CD4+ T-cells and B-cells when adoptively transferred into B-Myb 
depleted mice and challenged with VSV undergoes normal proliferation than compared to the 
host CD4+ T-cells and B-cells. This showed that B-Myb depletion has no adverse effect on 
adaptive immunity during viral infection and is crucial for immune activation by ensuring 
viral replication in APCs (Fig. 14). 
 VSV is a cytolytic virus, thus it leads to the lysis of the infected cell. If not controlled 
by innate and adaptive immune cells, VSV escapes to vital organs of the host, eventually 
causing death. As discussed VSV, possesses broad tissue tropism and is able to penetrate the 
blood-brain barrier106. In the case of its impaired replication in spleen during early 
replication, it escapes to CNS and brain causing cell death resulting in paralysis of the host. 
Our model of B-Byb is a conditional knockdown model and utilized knockdown of the 
desired (B-Myb) gene using a chemical entity (tamoxifen). Tamoxifen has been used in 
research for a long time, still its dose for mouse application varies from study to study. It has 
been shown that tamoxifen has the ability to cross blood-brain barrier in a dose-dependent 
manner which also depends on the age and weight of the mice193. Although even with the 
higher dose, the level of active tamoxifen metabolites in brain were observed only till day 4-5 
and were completely degraded by day 6 after the injection193. VSV at the dose of 2x106 PFU 
is controlled by the WT mice and thus is not found in CNS and brain of the host. However in 
B-Myb depleted mice, failure of virus control and antiviral immune activation leads to VSV 
escape to CNS by day 5-6 post tamoxifen injection (Fig. 15). Due to degradation of 
tamoxifen, B-Myb knockdown in CNS and brain, if it is even expressed there, is potentially 
ineffective, resulting in replication of VSV. This lead to the lysis of infected cells in CNS and 
brain resulting in observed paralysis in mice starting from hind legs and then spreading to the 
fore limbs.  
We showed the importance of B-Myb dependent early VSV replication in the activation of 
immune system leading to effective control of the virus and survival of the host.  
 
4.3 Immune signature of cell is independent of B-Myb 
 Interferon is a major cytokine produced during an antiviral response and is released 
by most of the cells and has a broad role in varying from direct antiviral to immune 
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modulatory. Lack of IFN response or the disruption of IFN signaling pathways leads to 
uncontrolled virus replication and host death129, 194. Many factors are known to contribute 
towards the secretion of IFN in an infection, which further ensures controlled early viral 
replication in order to mount an effective immune response. We have shown previously15 that 
IFN-I is involved in the enforced virus replication via usp18 ensuring immune activation. In 
the current study, we also observe reduced interferon production in B-Myb deficient mice on 
infection. This can be associated with the reduced viral replication in the spleen. Although as 
we discussed earlier the functional broad range of B-Myb, we wondered if B-Myb depletion 
have any adverse effect on immune signature of the cell. To ensure this, we checked with 
multiple immune stimulants the activation of signaling molecules involved in an antiviral 
immune signaling (Fig. 11, 12). We found that the immune signature remains intact with B-
Myb depletion. Here we show that despite B-Myb is a major transcription role, it doesn’t 
regulate the immune pathways activation and response. Thus, here we identify IFN-
independent role of B-Myb in early virus replication.  
4.4 Global dependence of viral replication on B-Myb 
We have shown that VSV replication is dependent on the activation and expression of 
B-Myb. Which is also crucial for the host to mount an efficient antiviral immune response.
VSV in a ssRNA virus and their replication cycle is completely different from that of DNA
viruses. RNA viruses consist of single or double strand of RNA and thus require RNA
polymerase called RNA-replicase and thus bypass the need for having a DNA copy, whereas
DNA viruses needs the transcription of the DNA genome into mRNA in order to synthesize
proteins required for virion assembly. Thus, both kinds of viruses opt for different host
factors and rely on different host machinery for their complete replication. With B-Myb
being a major transcription factor, its requirement by other RNA and DNA viruses was
explored.
We made use of two murine and two human virus models. In the case of murine 
viruses, we used another RNA virus LCMV and a DNA virus MCMV which have been 
shown to replicate in spleen during their early replication147. In line with our results of VSV 
replication, we observed abrogated early LCMV replication in CD169+ macrophages as well 
as reduced MCMV replication in marginal zone macrophages and CD11b+ cells in B-Myb 
depleted mice. With their reduced early replication, we investigated the adaptive immune 
response against both LCMV and MCMV in B-Myb deficient mice and significant reduction 
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in the CD8+ T-cell response in both the viruses (Fig. 16). These results validate that the B-
Myb dependent virus replication in both RNA and DNA viruses. Next, we investigated 
replication of human viruses HSV and HIV in B-myb knockdown cells. Interestingly we 
found similar results as that of murine viruses. The viral titers were significantly reduced in 
both HSV and HIV. 
 These results established the crucial importance of B-Myb in a broad range of virus 
replication. 
 
4.5 B-Myb assists viral replication via multiple host factors. 
Host factors are the important tools hijacked by the viruses. As discussed before these 
vary in function from the entry of virus all the way to the budding of virions. As these are 
provided by the host, they need to be transcribed by transcription factors. We hypothesized 
that B-Myb regulated some of these factors. B-Myb, a member of a transcription factor 
family and its association with the cell cycle G1/S phase signifies its broad transcriptional 
importance. In the Myb family, the binding sites of all three family member is conserved and 
thus specific target gens for B-Myb is still needs to be explored extensively. To check our 
hypothesis, we quantified the transcriptional expression of multiple known host factors for 
VSV and LCMV in B-Myb depleted mice and found that indeed their expression was 
significantly reduced.  We found that mostly expression of genes required for translational 
activity was significantly reduced. These results postulate the crucial transcriptional role of 
B-Myb for genes involved in translation. However, B-Myb is not known as the 
transcriptional activator of these genes and thus raises the question whether the observed host 
factor expression is a direct or indirect effect of B-Myb depletion. This requires more in-
depth study of B-Myb relation with host factors by transcription factor binding analysis and 
functional analysis amongst others.  
 
4.6 B-Myb facilitates LCMV replication in tumors 
We have shown B-Myb is an important regulator of virus replication and is involved 
in broad range of viruses. It is known that B-Myb is also expressed at high levels in multiple 
tumors, where it helps in tumor progression and proliferation. 
Viruses have been researched for their use in anti-tumor therapies for quite long now. 
Various viral models have been used, but the most accepted are the oncolytic models which 
have shown promising results in pre-clinical and clinical trials. Initially oncolytic viruses 
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have been sought as tumor lysing therapeutics but with the research they have shown to 
induce a systemic anti-tumor immune response195. These oncolytic viruses have been 
modified to adhere to the host requirement but still needs host factors for their replication158. 
These host factors as discussed earlier have important role in metabolism, cellular 
proliferation etc. In tumors, metabolic processes along with cell proliferation processes are 
up-regulated to ensure the energy requirements of the cell. Thus, this presents viruses with 
the abundance of cellular resources for their replication196, 197. 
 With our findings of B-Myb dependent viral replication, we explored the ability of 
cytopathic arenavirus to replicate in tumors. We observed that indeed our tumor models 
expressed high amount of phosphorylated B-Myb. Upon intravenous or peritumoral injection 
of LCMV, we found that LCMV preferentially replicated in tumor cells (Fig. 18) which leads 
to tumor suppression (Fig. 19) in multiple engrafted and spontaneous tumor models. Further 
analysis of tumor cells showed abundant expression of host-factors required for LCMV 
replication154 (Fig. A2). These host-factors are important for viral RNA transcriptional and 
translational process along with viral assembly and budding. These tumor cells thus act as 
treasure reserves for viruses.  
 
4.7 LCMV induces strong immune infiltration and IFN-I response 
 Effective immune activation is known to be the pre-requisite for effective anti-tumor 
virotherapy198. Expression of tumor antigens known as tumor-associated antigens (TAA) 
helps in the recognition of tumor cells by the immune system. However, tumor in-turn 
devises multiple ways to escape from immune recognition like by reducing expression of co-
stimulatory molecules, delivering inhibitory signals to immune cells, etc199, 200. Once the 
TAA are presented and recognized, it leads to infiltration of immune cells known as tumor 
infiltrating leukocytes (TIL). Enhancement of anti-tumor immunity can be divided into two 
aspects; 1. Increased efficient presentation of TAAs and production of local cytokines to 
attract more TILs, 2. Use of foreign antigen to attract TIL to tumor and enhance anti-tumor 
mediated immunity201. Thus, use of foreign antigen to attract TILs into tumors results in 
release of cytokines presents an effective and efficient strategy for anti-tumor therapy. 
 Arenaviruses are known to be efficient inducer of both humoral and cell-mediated 
immune response202. B-Myb dependent LCMV replication in tumors showed effective 
replication which further lead to increased immune infiltration in the tumors. LCMV 
treatment lead to significantly more T-cell and monocyte infiltration in tumors and well as 
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increased monocyte accumulation in draining lymph nodes (Fig. 20). This triggered an 
efficient interaction of TILs in the tumor microenvironment resulting in efficient recognition 
of TAAs. LCMV has an additional advantage over oncolytic viruses as it persists in tumor 
cells until an antiviral immune response is successfully established within the tumor.  
 
 Interferons are pleotropic cytokines which mediate anti-tumor effect in a wide array 
of ways203. Among major types of IFN present, Type-I IFN proficiently secreted by most of 
the cells including tumor cells. IFN-I types IFN-a and IFN-b have shown to have important 
function in cellular homeostasis and mediation of anti-tumor activity204, 205. IFN-mediate 
tumor immunotherapies have shown promising results, although it’s hard to predict the 
patient sensitivity towards IFN-I. Multiple reports have shown that IFN-I shows direct effect 
on tumor cells, when used alone or in combination with chemotherapy leads to better patient 
survival and have immunomodulatory effects206, 207. Use of viruses thus presents us a way to 
initiate and activate IFN-I response within the tumor cells, thus activating various anti-tumor 
signaling pathways208. We observed that indeed LCMV dependent tumor regression is IFN-I 
mediated (Fig. 21). 
 Oncolytic viruses possess some limitations as they are highly IFN-I responsive and 
thus so presence of IFN activity limits their replication in the tumor cells209. On the other 
hand, arenaviruses (LCMV) replication have shown not to be solely on IFN-I210 leading to its 
continuous replication in the tumor as observed. We show that LCMV replicates in the tumor 
for a longer extent leading to a prolong immune response and presence of immune cells with 
in the tumor. We observed that LCMV treatment leads to a high infiltration of monocytes 
which are one of the major inducer of IFN-I. Further investigation led to the identification of 
Ly6C+ monocytes which are basically responsible for the suppressive effect of LCMV on 
tumors via IFN-I dependent manner (Fig. 22). As discussed, IFN-I plays its anti-tumor role in 
variety of ways. Here we showed that LCMV infection indeed led to immune infiltration and 
resulted in high IFN response. 
 
4.8 LCMV induced IFN-I leads to reduced angiogenesis and apoptosis of tumor cells 
 Angiogenesis plays a critical role in the tumor growth and progression. This leads to 
the formation of new blood vessels for oxygen and nutrients delivery. Initiation of 
angiogenesis is done by various pro-angiogenic factors secreted by tumor cells, such as EGF, 
VEGF, FGF, etc. This process ensures tumor cell proliferation and continuous formation of 
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new vessels leading to metastasis178. Inhibition of angiogenesis specifically within the tumor 
is one anti-tumor strategy. IFN have known to have anti-angiogenesis function, thereby 
inhibiting/suppressing formation of new vessels and thus limiting tumor growth179. We 
showed here that LCMV induces a strong IFN-I upon which leads to suppression of tumor. 
Further investigation revealed that the tumor suppression observed was related to the down-
regulation of many pro-angiogenetic factors. Reduction of these factors results in the reduced 
MVD because of lack of formation of new vessels and thus increasing the vessel-vessel 
distance with-in the tumor with LCMV treatment. These findings were further verified with 
the reduction in CD31 expression in tumor which is majorly expressed by newly formed 
epithelial cells. Reduction if vessels in tumor microenvironment leads to the deficiency of 
oxygen and nutrients resulting in cell death which was observed in LCMV treated tumors 
(Fig. 25).   Thus, here we show that IFN-I induced by LCMV treatment acts as anti-tumor by 
suppressing the angiogenetic factors and thus restricting tumor growth. 
 
4.9 Role of T-cells in LCMV-mediated tumor therapy. 
 T-cells immunity holds one of the important role in the anti-tumor immunity176. T-cell 
infiltrates tumor microenvironment and acts by recognition of TAAs. Infiltration of T-cells 
leads to CTL mediated killing of tumor cells along with Th mediated activation of B-cells. 
Although tumor cells usually escape the T-cell mediated killing by down-modulation of 
MHC-I and MHC-II along with TAAs211. One alternative to improve adaptive immune/T-cell 
mediated anti-tumor activity is to selectively activates T-cells or to enhance the recruitment 
of T-cells in the tumor via chemical or biological way. Viruses have been used to modulate 
the recruitment of T-cells into tumors and also to enhance their activation212. Viral infection 
leads to the identification of viral antigen by immune system which then results in an anti-
viral response with-in the tumor. Killing of infected tumor cells results in antigen 
presentation of viral particles along with TAAs leading to anti-tumor T-cell activity. We 
show here that LCMV infection indeed results in infiltration of various immune cells 
including both CD8+ and CD4+ T-cells. Infiltration of CD8+ T-cells tends to be a worthy 
marker for the T-cell mediates anti-tumor effect. Although our further investigation proved 
that LCMV-dependent tumor suppression was largely independent of T-cells as analyzed by 
various functional T-cell deficient mice models (Tcrb-/- and Rag-/)- and was even worse in 
presence of virus-specific T-cells as it controlled the virus replication before it can assist in 
anti-tumor immunity (Fig. 23, 24). To recognize the role of tumor specific T-cells, we used 
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OVA-specific T-cells which showed enhanced anti-tumoral effect with LCMV treatment 
(Fig. 24). These results showed the ambiguous role of T-cells in the LCMV-mediated anti-
tumor activity and that it is majorly based on recruitment IFN-I producing Ly6C+ cells. 
However, we show that combination of tumor-specific T-cells and LCMV therapy have 
better anti-tumor effect and thus LCMV can be combined with existing anti-tumor therapies 
for improved results.  
 
4.10 LCMV virotherapy presents better immune modulation and anti-tumor function 
 Oncolytic viruses have been studied and used in the anti-tumoral activities. This is 
majorly based on the activity of viruses to infect and lyse the cell. Use and development of 
oncolytic viruses as anti-cancer agent is recognized throughout the world. This can be seen 
by the approval of an oncolytic herpesvirus (Talimogene Iaherparepvec, Amgen) for 
melanoma patients213. Tumor regression by oncolytic viruses is an attribute by their lysis 
ability along with the induction of inflammatory response214. Although many studies are 
being performed using oncolytic viruses, these still present slight advantage over tumor 
immunity and need to be modified to a greater extent to prevent non-tumor host-cell damage. 
We used non-oncolytic arenavirus LCMV as anti-tumor viral therapy. Arenaviruses are 
cytopathic in nature and induce immune response which is majorly regulated by cell-
mediated immunity. In this study, we observed that LCMV treatment leads to tumor 
regression over a prolong period of time. This observed tumor regression was observed in 
many tumor models we investigated and was based on humoral and cell-mediated immunity. 
Upon comparison with other pre-clinical/clinical oncolytic viruses; rVSV, rVACV, we found 
that LCMV has better efficiency and efficacy in suppression of tumor. The reduced effect of 
oncolytic viruses can be explained by their need of defects in IFN-I pathway for replication in 
tumors215. Viral treatment in oncolytic viruses also depends on the dose and site of 
administration. Upon increasing the dose of compared oncolytic viruses to over 100-fold, 
they still showed significantly lower tumor regression and host survival compared to LCMV 
(Fig. 26). We show that LCMV is therapeutically much more potent and efficient anti-tumor 
virotherapy than rVSV and rVACV. However, the application of LCMV as a therapeutic 
intervention in the clinic is still in the early preclinical stages. We have used the laboratory 
strain of LCMV (LCMV-WE) and its impact on human beings can still be quite harmful. 
Arenaviruses have been related to hemorrhagic fevers and thus LCMV needs to be carefully 
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manipulated in order to have no or minimal effect on host health, before being used in 
clinical scenario.  
 
 In this study, we have identified B-Myb as one of the major host-factor which is 
activated (phosphorylated) during active virus replication and that it is required by majority 
of DNA and RNA viruses. B-Myb expression is crucial for viral replication as virus shows 
severely reduced replication in absence of B-Myb. B-Myb dependent viral replication is a 
result of B-Myb dependent expression of multiple host factors responsible for viral 
replication. We show that B-Myb dependent early virus replication is important for the host 
to mount an efficient innate and adaptive immune response. In the further study, we have 
identified B-Myb assisted LCMV replication as an efficient and effective anti-tumor 
treatment. We show that LCMV treatment results in immune infiltration with in the tumor. 
We also showed that arenavirus treatment results in better tumor control and host survival 
than oncolytic viruses and the observed tumor regression is largely dependent on IFN-I 
producing Ly6C+ produced. 											 			
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APPENDIX 
Figure A1:  Dot-plot of CD169 staining from CD-169 DTR and Control mice treated with 
diphtheria toxin (30µg/kg) (n=3) (top panel).  Representative histograms of phospho-B-Myb 
staining of different cell types from spleen of naïve and 2x108 PFU VSV treated C57BL6/J 
mice analyzed 8 hrs p.i. (n=5).  
Figure A2:  Quantitative analysis of mRNA expression of viral host factors from MOPC 
tumors and control pharynx tissue (n=5) 
A1 
A2 
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ABBREVIATIONS 
Ab   Antibody 
ALT  Alanine aminotransferase 
APC  Antigen Presenting Cells 
BMDM Bone marrow derived  
  macrophages 
BMDC Bone marrow derived  
  dendritic cells 
CD  Cluster of Differentiation 
cDNA  Complementary DNA 
CFSE  Carboxyfluorescein  
  succinimidyl ester 
DC  Dendritic cell 
DEPC  Diethyl pyrocarbonate 
DMEM Dulbecco’s modified eagle 
  medium 
DNA  Deoxyribonucleic acid 
ELISA  Enzyme linked immune 
  sorbent assay 
FACS  Fluorescence activated 
  cell sorter 
FCS  Fetal calf serum 
GP  Glycoprotein 
HSV  Herpes Simplex virus 
HIV  Human immuno- 
  deficiency virus 
i.p.  intra-peritoneal 
i.v.  intra-venous 
i.t.  intra-tumoral 
IFN  Interferon 
IL  Interleukin 
IMDM  Iscove’s modified  
  dulbecco’s medium 
 
 
LPS  Lipo-polysaccharide 
MCMV Murine cytomegalovirus 
MVD  Micro-vessel density 
NP  Nucleoprotein 
PBS  Phosphate buffered saline 
p.i.  post-infection 
p.t.  post-treatment 
PCR  Polymerase chain reaction 
PFU  plaque forming units 
RNA  Ribonucleicacid 
RPM  Rotations per minute 
RT  Room temperature 
OVA  Ovalabumin 
SDS  Sodium dodecyl sulphate 
TCR  T-cell receptor 
TLR  Toll-like receptor 
UV  Ultraviolet 
VSV  Vesicular stomatitis virus 
LCMV  Lymphocytic   
  choriomeningitis virus 
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